Use of induced vesicle in preparation of antitumor drug for use in combination with immunotherapeutic agent

By combining induced vesicles generated from apoptosis in mesenchymal stem cells with immunotherapeutic agents, the tumor microenvironment is altered, addressing the issue of unsatisfactory efficacy of ICB therapy and enhancing the therapeutic effect on tumors.

WO2026233289A1PCT designated stage Publication Date: 2026-11-12SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/094799
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current immune checkpoint blockade therapy is not ideal in some solid tumors such as hepatocellular carcinoma, mainly because the infiltration of immunosuppressive TAM and Treg cells in the tumor microenvironment has not been effectively altered, leading to reduced efficacy of ICB treatment.

Method used

By combining induced vesicles generated from apoptosis induced in mesenchymal stem cells with immunotherapeutic agents, the tumor microenvironment can be altered using induced vesicles, thereby enhancing immune cell function and inhibiting immunosuppressive metabolism.

Benefits of technology

It improved the efficacy of immune checkpoint blockade therapy, improved the immune balance of the tumor microenvironment, and enhanced the therapeutic effect on tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026094799_12112026_PF_FP_ABST
    Figure CN2026094799_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure belongs to the field of biomedicine, and relates to the use of an induced vesicle in the preparation of an antitumor drug for use in combination with an immunotherapeutic agent. Provided in the present disclosure is the use of an induced vesicle in the preparation of an antitumor drug for use in combination with an immunotherapeutic agent. Studies of the present disclosure find that an apoptotic vesicle bidirectionally regulates the metabolic balance of immune cells to eliminate the tumor immunosuppressive microenvironment, and promotes the efficacy of immune checkpoint blockade therapy. The present disclosure focuses on the bottleneck problem in clinical tumor immunotherapy, and combines an induced vesicle targeting tumor metabolic checkpoints with an immune checkpoint inhibitor, thereby effectively optimizing the efficacy of immunotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

Use of induced vesicles in the preparation of antitumor drugs for use in combination with immunotherapy agents Technical Field

[0001] This disclosure pertains to the field of biomedicine and relates to the use of an induced vesicle in the preparation of an antitumor drug for use in combination with an immunotherapy agent. Background Technology

[0002] Tumor aerobic glycolysis creates an unfavorable tumor microenvironment (TME), disrupting the metabolic balance of immune cells and enabling tumor cells to evade immune responses (Reinfeld, BI, et al. (2022)). Immune checkpoint blockade (ICB) therapy restores effector T cell responses and has shown unprecedented clinical efficacy in several cancers (Callahan, MK, et al. (2016)). However, in the treatment of certain solid tumors such as hepatocellular carcinoma (HCC) (Zhu, AX, et al. (2022); Finn, RS, et al. (2020)), the therapeutic effect of ICB is not ideal. Studies have found (Zhu, AX, et al. (2022); Togashi, Y., et al. (2019)) that decreased clinical efficacy of ICB is associated with the failure to alter or even further increase in the infiltration of TME immunosuppressive M2 tumor-associated macrophages (TAMs) and regulatory T (Treg) cells after treatment (Sharma, P., et al. (2017); Arlauckas, SP, et al. (2017); Dong, L., et al. (2021)). Therefore, further exploration of effective strategies to rebalance the immune microenvironment and improve the efficacy of ICB treatment is needed. Apoptosis is essential for regulating immune homeostasis. The lack of apoptosis leads to autoimmune diseases (Bouillet, P., et al. (1999)), while overactive apoptosis leads to neurodegenerative diseases (Mattson, MP, et al. (2000)), HIV (Gougeon, ML, et al. (2003)) and chronic idiopathic neutropenia (CIN) (Papadaki, HA, et al., 2003).

[0003] Apoptotic cells produce a large number of extracellular vesicles (EVs) called apoptotic vesicles (apoVs), which contain various cellular components, including proteins, nucleic acids, and lipids (Wiklander, OPB, et al. (2019)). Mesenchymal stem cells (MSCs) play a crucial role in maintaining tissue homeostasis (Friedenstein, AJ, et al. (1974); Liu, Y., et al. (2011); Sun, L., et al. (2009)). MSCs are a promising cellular resource for generating apoVs for therapeutic purposes, including improving osteoporosis (Liu, D., et al. (2018)), sepsis (Ou, Q., et al. (2022)), type 2 diabetes (Zheng, C., et al. (2021)), lupus erythematosus (Wang, R., et al. (2023)), and ameliorhythmia multiple myeloma (MM) (Wang, J., et al. (2021)). Conversely, tumor cell-derived apoVs promote tumor cell proliferation and metastasis, exacerbating tumor development and recurrence (Pavlyukov, MS, et al. (2018)).

[0004] However, the detailed functions of apoVs from different cells in the immunosuppressive TME remain unclear. Tumors adapt to aerobic glycolysis for their survival (Warburg, O. (1956)). The resulting glucose consumption and lactate production limit the immune cell glycolysis and nicotinamide adenine dinucleotide (NAD) required for the proliferation of effector T cells and inflammatory M1 macrophages. + (Leone, RD, et al. (2020); Brand, A., et al. (2016)). However, Treg cells and M2 macrophages use lactate to synthesize NAD+ (Leone, RD, et al. (2020); Brand, A., et al. (2016)). +It is reduced to nicotinamide adenine dinucleotide hydrate (NADH) to maintain oxidative phosphorylation (OXPHOS) and enhance its immunosuppressive phenotype (Colegio, OR, et al. (2014); Watson, MJ (2021)). Current metabolic checkpoint therapies focus on inhibiting single targets of aerobic glycolysis in tumor cells or adaptive changes in specific types of immune cells in a highly glycolytic TME (Zhang, L., et al. (2023); Guo, C., et al. (2023)). Given the complexity of the imbalanced immunosuppressive metabolic conditions in the TME, further exploration is needed to improve the treatment of ICB. Summary of the Invention

[0005] In some embodiments, this disclosure provides the use of induced vesicles in the preparation of antitumor drugs for use in combination with immunotherapeutic agents.

[0006] In some embodiments, this disclosure provides the use of immunotherapeutic agents in the preparation of antitumor drugs used in combination with induced vesicles.

[0007] In some implementations, the induced vesicles are vesicles generated by inducing apoptosis in stem cells or somatic cells when they are in normal survival by adding external factors.

[0008] In some implementations, the induction method includes adding astrocytocin, ultraviolet irradiation, starvation, or thermal stress.

[0009] In some implementations, the stem cells are selected from mesenchymal stem cells.

[0010] In some implementations, the mesenchymal stem cells are derived from bone marrow, dental pulp, urine, oral cavity, fat, placenta, umbilical cord, periosteum, tendon, or peripheral blood.

[0011] In some implementations, the diameter of the induced vesicles is approximately 0.03-10 μm.

[0012] In some implementations, the diameter of the induced vesicles is approximately 0.03-6 μm.

[0013] In some implementations, the diameter of the induced vesicles is approximately 0.03-4.5 μm.

[0014] In some implementations, the diameter of the induced vesicles is approximately 0.03-1 μm.

[0015] In some implementations, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 1–1500 nM.

[0016] In some implementations, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 10–800 nM.

[0017] In some implementations, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 100–800 nM.

[0018] In some implementations, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 200–700 nM.

[0019] In some implementations, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 300–600 nM.

[0020] In some implementations, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 400–600 nM.

[0021] In some implementation schemes, the time for inducing apoptosis by adding astrosporin is approximately 2 to 24 hours.

[0022] In some implementations, the time for inducing apoptosis by adding astrosporin is approximately 2 to 15 hours.

[0023] In some implementations, the time for inducing apoptosis by adding astrosporin is approximately 2 to 10 hours.

[0024] In some implementations, the induced vesicles express the marker Syntaxin 4 at a higher rate than MSCs or exosomes of the same origin.

[0025] In some implementations, the markers also include one or more of Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5.

[0026] In some implementations, the induced vesicles are highly expressed using the biomarkers Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5.

[0027] In some implementations, the induced vesicles express higher levels of the biomarkers Annexin V, Flotillin-1, Cadherin 11, and Integrin alpha 5 than MSCs or exosomes of the same origin.

[0028] In some implementations, the induced vesicles are highly expressed using the biomarkers cleaved caspase-3, Calnexin, Calreticulin, CD63, CD9, caspase-3, and CD44.

[0029] In some embodiments, the method for obtaining the induced vesicles includes the steps of: (1) culturing mesenchymal stem cells; (2) collecting the culture supernatant of the mesenchymal stem cells; and (3) separating the vesicles from the culture supernatant in step (2). In some embodiments, the step of culturing mesenchymal stem cells in step (1) includes: (4) isolating mesenchymal stem cells from the tissue; and (5) adding culture medium to culture the mesenchymal stem cells; wherein the culture medium of the mesenchymal stem cells is contacted with an apoptosis inducer. In some embodiments, the method for separating the vesicles in step (3) includes using ultracentrifugation to separate the vesicles. In some embodiments, the step of separating the vesicles by ultracentrifugation includes: (a) performing a first centrifugation on the collected culture supernatant and collecting the supernatant; (b) performing a second centrifugation on the supernatant collected in step (a) and collecting the supernatant; (c) performing a third centrifugation on the supernatant collected in step (b) and collecting the precipitate; and (d) performing a fourth centrifugation on the precipitate collected in step (c) and collecting the precipitate. In some embodiments, the first centrifugation is approximately 500-1500g for 5-30 minutes. In some embodiments, the first centrifugation is approximately 500-1000g for 5-20 minutes. In some embodiments, the first centrifugation is approximately 500-900g for 5-15 minutes. In some embodiments, the second centrifugation is approximately 1000-3000g for 5-30 minutes. In some embodiments, the second centrifugation is approximately 1500-2500g for 5-20 minutes. In some embodiments, the second centrifugation is approximately 1500-2200g for 5-15 minutes. In some embodiments, the third centrifugation is approximately 10000-30000g for 15-60 minutes. In some embodiments, the third centrifugation is approximately 12000-25000g for 20-60 minutes. In some embodiments, the third centrifugation is approximately 12000-20000g for 20-40 minutes. In some embodiments, the fourth centrifugation is performed at approximately 10,000-30,000 g for 15-60 minutes. In some embodiments, the fourth centrifugation is performed at approximately 12,000-25,000 g for 20-60 minutes. In some embodiments, the fourth centrifugation is performed at approximately 12,000-20,000 g for 20-40 minutes.

[0030] In some implementations, the immunotherapeutic agent is an immunotherapeutic drug.

[0031] In some embodiments, the immunotherapeutic agent comprises an anti-PD-1 antibody or an anti-PD-L1 antibody. In some embodiments, the anti-PD-1 antibody is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, CT-011, AMP-224, MPDL3280A, MEDI4736, or MDX-1105. In some embodiments, the anti-PD-L1 antibody is avirumab, durvalumab, or atezolizumab.

[0032] In some embodiments, the tumor is selected from solid tumors or hematologic malignancies. In some embodiments, the solid tumor is selected from liver cancer.

[0033] In some embodiments, this disclosure provides a technical solution for treating tumors by combining an inducible vesicle with an immunotherapeutic agent. In some embodiments, the term "combination" is interpreted broadly, for example, a pharmaceutical composition, a pharmaceutical kit, and a gene combination of an inducible vesicle gene and an immunotherapeutic agent at the molecular level.

[0034] As used herein, the term "drug combination" refers to a product obtained by mixing or combining one or more active ingredients, including fixed and non-fixed combinations of active ingredients. The terms "co-administration" or "combination administration" as used herein are intended to encompass the administration of selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered via the same route of administration or at the same time. As used herein, the term "fixed combination" means the simultaneous administration of an active ingredient (e.g., an immunotherapy agent and an inducing vesicle) to a patient in the form of a single entity or dose. As used herein, the term "non-fixed combination" means the simultaneous, co-administration, or sequential administration of an active ingredient (e.g., an immunotherapy agent and an inducing vesicle) to a patient as separate entities, wherein such administration provides therapeutically effective levels of both compounds in vivo, preferably at the same time. For example, a non-fixed combination may be two capsules each containing one active ingredient, with the aim of treating the patient in vivo with both active ingredients together. As used in this disclosure, “combined use” or “conjunctive use” means that two or more active substances may be administered to a subject simultaneously or sequentially as a single formulation in any order (e.g., simultaneously, sequentially, or at intervals) in a mixture.

[0035] As used in this disclosure, the term "in combination with" when referring to administering multiple reagents to a subject means administering the first reagent to the subject at least one other (i.e., a second, third, fourth, fifth, etc.) reagent. As used in this disclosure, if the biological effect resulting from the administration of the first reagent persists in the subject's body when the second reagent is administered, causing the therapeutic effects of the first and second reagents to be additive, then a reagent (e.g., an inducible vesicle) is considered to be administered in combination with the second reagent (e.g., an immunotherapy agent). Since administration of the first reagent (e.g., an inducible vesicle) provides a therapeutic effect over a longer period, and administration of the second reagent (e.g., an immunotherapy agent) provides its therapeutic effect while the therapeutic effect of the first reagent is still ongoing, the second reagent is considered to be administered in combination with the first reagent, even if the first reagent may have been administered at a point in time distant from the time of administration of the second reagent (e.g., days or weeks). In some embodiments, if the first and second reagents are administered simultaneously (within 30 minutes of each other), concurrently, or sequentially, then the first reagent is considered to be administered in combination with the second reagent. In some embodiments, if the first reagent and the second reagent are administered within approximately 24 hours of each other (e.g., within approximately 12 hours of each other, within approximately 6 hours of each other, within approximately 2 hours of each other, or within approximately 30 minutes of each other), the first reagent is considered to be administered "simultaneously" with the second reagent. The term "in combination with" should also be understood to apply to situations where the first and second reagents are co-formulated in a single pharmaceutically acceptable formulation and that co-formulation is administered to the subject. In some embodiments, the inducing vesicles and the immunotherapeutic agent are administered or applied sequentially, for example, after one reagent is administered, one or more other reagents are administered. In some embodiments, the inducing vesicles and the immunotherapeutic agent are administered simultaneously, for example, two or more reagents are administered at the same time or approximately at the same time; these two or more reagents may be present in two or more separate formulations or combined into a single formulation (i.e., a co-formulation). Regardless of whether these reagents are administered sequentially or simultaneously, as used in this disclosure, they are considered to be administered / used in combination.

[0036] In some embodiments, this disclosure provides the use of induced vesicles in the preparation of medicaments for improving or treating poor prognoses in tumor immunotherapy.

[0037] In some implementations, the induced vesicles are vesicles generated by inducing apoptosis in stem cells or somatic cells when they are in normal survival by adding external factors.

[0038] In some implementations, the induction method includes adding astrocytocin, ultraviolet irradiation, starvation, or thermal stress.

[0039] In some implementations, the stem cells are selected from mesenchymal stem cells.

[0040] In some implementations, the mesenchymal stem cells are derived from bone marrow, dental pulp, urine, oral cavity, fat, placenta, umbilical cord, periosteum, tendon, or peripheral blood.

[0041] In some embodiments, the diameter of the inducible vesicle is approximately 0.03-10 μm. In some embodiments, the diameter of the inducible vesicle is approximately 0.03-6 μm. In some embodiments, the diameter of the inducible vesicle is approximately 0.03-4.5 μm. In some embodiments, the diameter of the inducible vesicle is approximately 0.03-1 μm.

[0042] In some embodiments, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 1–1500 nM. In some embodiments, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 10–800 nM. In some embodiments, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 100–800 nM. In some embodiments, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 200–700 nM. In some embodiments, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 300–600 nM. In some embodiments, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 400–600 nM.

[0043] In some embodiments, the time to apoptosis induced by adding asteroidin is approximately 2–24 hours. In some embodiments, the time to apoptosis induced by adding asteroidin is approximately 2–15 hours. In some embodiments, the time to apoptosis induced by adding asteroidin is approximately 2–10 hours.

[0044] In some embodiments, the induced vesicles express the biomarker Syntaxin 4 more than syngeneic MSCs or exosomes. In some embodiments, the biomarker further includes one or more of Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5. In some embodiments, the induced vesicles highly express the biomarkers Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5. In some embodiments, the induced vesicles express the biomarkers Annexin V, Flotillin-1, Cadherin 11, and Integrin alpha 5 more than syngeneic MSCs or exosomes. In some embodiments, the induced vesicles highly express the biomarkers cleaved caspase-3, Calnexin, Calreticulin, CD63, CD9, caspase-3, and CD44.

[0045] In some implementations, the tumor immunotherapy is a treatment using anti-PD-1 antibodies or anti-PD-L1 antibodies.

[0046] In some embodiments, the anti-PD-1 antibody is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, CT-011, AMP-224, MPDL3280A, MEDI4736, or MDX-1105.

[0047] In some implementations, the anti-PD-L1 antibody is averumatumab, devalumatumab, or atezolizumab.

[0048] In some embodiments, the tumor is selected from solid tumors or hematologic malignancies. In some embodiments, the solid tumor is selected from liver cancer.

[0049] In some embodiments, this disclosure provides the use of LDHA detection reagents in extracellular vesicles in the preparation of tumor diagnostic or prognostic reagents or kits.

[0050] In some implementations, the source samples of the extracellular vesicles include blood, serum, plasma, tissue, lysate, extracellular fluid, tissue fluid, lymph, cerebrospinal fluid, aqueous humor, sputum, saliva, urine, or feces.

[0051] In some embodiments, the extracellular vesicles are derived from tumor patients. In other embodiments, the extracellular vesicles are derived from tumor cells.

[0052] In some implementations, the detection reagent detects the expression level of the LDHA gene.

[0053] In some implementations, the detection reagent detects the mRNA expression level of the LDHA gene.

[0054] In some implementations, the detection reagent detects the protein expression level of the LDHA gene.

[0055] In some embodiments, the detection reagent is selected from at least one of the following groups: quantitative PCR dyes, quantitative PCR primers, quantitative PCR probes, antibodies, functional fragments of antibodies, or conjugated antibodies.

[0056] In some implementations, the kit is selected from at least one group consisting of qPCR kits, immunoblotting kits, immunochromatographic kits, flow cytometry kits, immunohistochemistry kits, ELISA kits, or electrochemiluminescence kits.

[0057] In some implementations, the tumor is a solid tumor or a hematoma.

[0058] In some implementations, the solid tumor is selected from liver cancer.

[0059] In some implementations, the method for extracting extracellular vesicles includes the steps of:

[0060] (1) Centrifuge the collected samples for the first time and take the supernatant;

[0061] (2) Centrifuge the supernatant collected in step (1) a second time and take the supernatant;

[0062] (3) Centrifuge the supernatant collected in step (2) for the third time and take the precipitate;

[0063] (4) Wash the precipitate collected in step (3).

[0064] In some embodiments, the first centrifugation is approximately 500-1500g for 5-30 minutes. In some embodiments, the second centrifugation is approximately 1000-3000g for 5-30 minutes. In some embodiments, the third centrifugation is approximately 10000-30000g for 15-60 minutes. In some embodiments, the first centrifugation is approximately 600-1500g for 5-30 minutes. In some embodiments, the first centrifugation is approximately 600-1000g for 5-30 minutes. In some embodiments, the second centrifugation is approximately 1500-3000g for 5-30 minutes. In some embodiments, the second centrifugation is approximately 1800-3000g for 5-30 minutes. In some embodiments, the third centrifugation is approximately 10000-20000g for 15-60 minutes. In some embodiments, the third centrifugation is approximately 15000-20000g for 15-60 minutes.

[0065] In some embodiments, the washing involves adding the precipitate obtained in step (3) to a washing solution, centrifuging at 10,000-30,000 g for 15-60 minutes, and collecting the precipitate to obtain the extracellular vesicles.

[0066] In some embodiments, this disclosure provides the use of an LDHA detection reagent in the preparation of prognostic diagnostic reagents or kits for cancer patients after immunotherapy.

[0067] In some implementations, the test samples for the test reagent include blood, serum, plasma, tissue, lysate, extracellular fluid, tissue fluid, lymph, cerebrospinal fluid, aqueous humor, sputum, saliva, urine, or feces.

[0068] In some implementations, the test sample for the detection reagent is selected from extracellular vesicles.

[0069] In some implementations, the detection reagent detects the expression level of the LDHA gene.

[0070] In some implementations, the detection reagent detects the mRNA expression level of the LDHA gene.

[0071] In some implementations, the detection reagent detects the protein expression level of the LDHA gene.

[0072] In some embodiments, the detection reagent is selected from at least one of the following groups: quantitative PCR dyes, quantitative PCR primers, quantitative PCR probes, antibodies, functional fragments of antibodies, or conjugated antibodies.

[0073] In some implementations, the kit is selected from at least one group consisting of qPCR kits, immunoblotting kits, immunochromatographic kits, flow cytometry kits, immunohistochemistry kits, ELISA kits, or electrochemiluminescence kits.

[0074] In some implementations, the tumor is a solid tumor or a hematoma.

[0075] In some implementations, the solid tumor is selected from liver cancer.

[0076] In some embodiments, this disclosure provides a reagent combination or kit comprising:

[0077] Extraction reagents for extracellular vesicles and reagents for LDHA detection.

[0078] In some embodiments, the extraction reagent or kit for the extracellular vesicles includes extraction tools or extraction reagents.

[0079] In some implementations, the extraction tool includes blood collection tubes, centrifuge tubes, centrifuges, or pipettes.

[0080] In some embodiments, the extraction reagent includes a buffer solution.

[0081] In some implementations, the buffer solution includes PBS.

[0082] In some embodiments, the method for extracting extracellular vesicles includes the following steps: (1) centrifuging the collected sample for the first time and collecting the supernatant; (2) centrifuging the supernatant collected in step (1) for the second time and collecting the supernatant; (3) centrifuging the supernatant collected in step (2) for the third time and collecting the precipitate; and (4) washing the precipitate collected in step (3). In some embodiments, the first centrifugation is approximately 500-1500g for 5-30 minutes. In some embodiments, the second centrifugation is approximately 1000-3000g for 5-30 minutes. In some embodiments, the third centrifugation is approximately 10000-30000g for 15-60 minutes. In some embodiments, the first centrifugation is approximately 600-1500g for 5-30 minutes. In some embodiments, the first centrifugation is approximately 600-1000g for 5-30 minutes. In some embodiments, the second centrifugation is approximately 1500-3000g for 5-30 minutes. In some embodiments, the second centrifugation is performed at approximately 1800-3000g for 5-30 minutes. In some embodiments, the third centrifugation is performed at approximately 10000-20000g for 15-60 minutes. In some embodiments, the third centrifugation is performed at approximately 15000-20000g for 15-60 minutes. In some embodiments, the washing involves adding washing solution to the precipitate obtained in step (3), centrifuging at 10000-30000g for 15-60 minutes, and collecting the precipitate to obtain the extracellular vesicles.

[0083] In some implementations, the sample includes blood, serum, plasma, tissue, lysate, extracellular fluid, tissue fluid, lymph, cerebrospinal fluid, aqueous humor, sputum, saliva, urine, or feces.

[0084] In some implementations, the reagent is a tumor diagnostic reagent or a prognostic diagnostic reagent for cancer patients after immunotherapy.

[0085] In some embodiments, the tumor is a solid tumor or a hematoma. In some embodiments, the solid tumor is selected from liver cancer.

[0086] In some embodiments, this disclosure provides for the use of the described reagent combination or kit in the preparation of tumor diagnostic reagents or kits or prognostic diagnostic reagents or kits for cancer patients after immunotherapy.

[0087] In some embodiments, this disclosure provides a drug combination for treating tumors, comprising: inducible vesicles, and an immunotherapeutic agent.

[0088] In some embodiments, the drug combination is a pharmaceutical composition or a pharmaceutical kit. In some embodiments, the pharmaceutical composition comprises a mixture of inducing vesicles and an immunotherapeutic agent.

[0089] In some implementations, the pharmaceutical kit comprises individually packaged inducible vesicles and individually packaged immunotherapeutic agents.

[0090] The pharmaceutical kit differs from a composition in that the inducible vesicles are not in the dosage form of the immunotherapy agent, but are individually packaged (e.g., containing inducible vesicles in pills, capsules, tablets, or ampoules; and the immunotherapy agent in other pills, capsules, tablets, or ampoules). In some embodiments, the inducible vesicles, the immunotherapy agent, and combinations thereof may also contain one or more adjuvants. An adjuvant is a component in the pharmaceutical composition that assists in the efficacy of the drug. The pharmaceutical kit may also contain individually packaged inducible vesicles and individually packaged immunotherapy agents. The administration of the inducible vesicles and the immunotherapy agent in the pharmaceutical kit may be simultaneous or in any sequential order, such as administering the immunotherapy agent before the inducible vesicles, or administering the inducible vesicles after the immunotherapy agent, or administering both simultaneously. In various embodiments, the patient may be a mammal.

[0091] In some implementations, the immunotherapeutic agent is a treatment using an anti-PD-1 antibody or an anti-PD-L1 antibody.

[0092] In some embodiments, the anti-PD-1 antibody is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, CT-011, AMP-224, MPDL3280A, MEDI4736, or MDX-1105.

[0093] In some implementations, the anti-PD-L1 antibody is averumatumab, devalumatumab, or atezolizumab.

[0094] In some implementations, the tumor is a solid tumor or a hematoma.

[0095] In some implementations, the solid tumor is selected from liver cancer.

[0096] In some implementations, the induced vesicles are vesicles generated by inducing apoptosis in stem cells or somatic cells when they are in normal survival by adding external factors.

[0097] In some implementations, the induction method includes adding astrocytocin, ultraviolet irradiation, starvation, or thermal stress.

[0098] In some implementations, the stem cells are selected from mesenchymal stem cells.

[0099] In some implementations, the mesenchymal stem cells are derived from bone marrow, dental pulp, urine, oral cavity, fat, placenta, umbilical cord, periosteum, tendon, or peripheral blood.

[0100] In some embodiments, the diameter of the inducible vesicle is approximately 0.03-10 μm. In some embodiments, the diameter of the inducible vesicle is 0.03-6 μm. In some embodiments, the diameter of the inducible vesicle is approximately 0.03-4.5 μm. In some embodiments, the diameter of the inducible vesicle is approximately 0.03-1 μm.

[0101] In some embodiments, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 1–1500 nM. In some embodiments, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 10–800 nM. In some embodiments, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 100–800 nM. In some embodiments, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 200–700 nM. In some embodiments, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 300–600 nM. In some embodiments, apoptosis is induced by adding asteroidin, wherein the concentration of asteroidin is approximately 400–600 nM.

[0102] In some embodiments, the time to apoptosis induced by adding asteroidin is approximately 2–24 hours. In some embodiments, the time to apoptosis induced by adding asteroidin is approximately 2–15 hours. In some embodiments, the time to apoptosis induced by adding asteroidin is approximately 2–10 hours.

[0103] In some embodiments, the induced vesicles express the biomarker Syntaxin 4 more than syngeneic MSCs or exosomes. In some embodiments, the biomarker further includes one or more of Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5. In some embodiments, the induced vesicles highly express the biomarkers Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5. In some embodiments, the induced vesicles express the biomarkers Annexin V, Flotillin-1, Cadherin 11, and Integrin alpha 5 more than syngeneic MSCs or exosomes. In some embodiments, the induced vesicles highly express the biomarkers cleaved caspase-3, Calnexin, Calreticulin, CD63, CD9, caspase-3, and CD44.

[0104] In some embodiments, this disclosure provides a tumor diagnostic system comprising: a detection component for LDHA in extracellular vesicles derived from a tumor sample, and a result determination component.

[0105] In some embodiments, the detection component for LDHA in the extracellular vesicles contains the reagent combination or kit.

[0106] In some implementations, the result determination component is used to output the risk of tumor development and / or tumor type based on the LDHA results detected by the detection component in the extracellular vesicles.

[0107] In some implementations, the disease risk is determined by comparing the detection results of LDHA in extracellular vesicles of the test sample and the normal sample using a result judgment component. When there is a significant or extremely significant difference in LDHA in extracellular vesicles between the test sample and the normal sample, the result judgment component outputs that the test sample has a high risk of developing tumors.

[0108] In some embodiments, the tumor is a solid tumor or a hematoma. In some embodiments, the solid tumor is selected from liver cancer.

[0109] In some embodiments, this disclosure provides a method for treating tumors, the method comprising administering the pharmaceutical composition to a patient in need.

[0110] In some embodiments, this disclosure provides a method for diagnosing tumors, the method comprising:

[0111] Using the aforementioned reagent combination or kit, the expression level of LDHA in extracellular vesicles of the sample to be tested was detected;

[0112] Based on the deviation between the LDHA expression level of extracellular vesicles in the test sample and the LDHA expression level of extracellular vesicles in normal samples, it is determined whether the patient has a tumor or is at risk of developing a tumor.

[0113] In some implementations, the LDHA expression level is the expression level of the LDHA gene, the mRNA expression level of the LDHA gene, or the protein expression level of the LDHA gene.

[0114] In some implementations, a cutoff value of ≥50.2000% for the LDHA expression level of extracellular vesicles in the test sample is used to determine whether the patient has a tumor or is at risk of developing a tumor.

[0115] In some implementations, the sample to be tested includes blood, serum, plasma, tissue, lysate, extracellular fluid, tissue fluid, lymph, cerebrospinal fluid, aqueous humor, sputum, saliva, urine, or feces;

[0116] In some implementations, the method for extracting extracellular vesicles includes the steps of:

[0117] (1) Centrifuge the collected samples for the first time and take the supernatant;

[0118] (2) Centrifuge the supernatant collected in step (1) a second time and take the supernatant;

[0119] (3) Centrifuge the supernatant collected in step (2) for the third time and take the precipitate;

[0120] (4) Wash the precipitate collected in step (3);

[0121] In some embodiments, the first centrifugation is approximately 500-1500g for 5-30 minutes. In some embodiments, the second centrifugation is approximately 1000-3000g for 5-30 minutes. In some embodiments, the third centrifugation is approximately 10000-30000g for 15-60 minutes. In some embodiments, the first centrifugation is approximately 600-1500g for 5-30 minutes. In some embodiments, the first centrifugation is approximately 600-1000g for 5-30 minutes. In some embodiments, the second centrifugation is approximately 1500-3000g for 5-30 minutes. In some embodiments, the second centrifugation is approximately 1800-3000g for 5-30 minutes. In some embodiments, the third centrifugation is approximately 10000-20000g for 15-60 minutes. In some embodiments, the third centrifugation is approximately 15000-20000g for 15-60 minutes. In some embodiments, the washing involves adding the precipitate obtained in step (3) to a washing solution, centrifuging at 10,000-30,000 g for 15-60 minutes, and collecting the precipitate to obtain the extracellular vesicles.

[0122] In some implementations, the tumor is a solid tumor or a hematoma.

[0123] In some implementations, the solid tumor is selected from liver cancer.

[0124] This disclosure also includes the following:

[0125] item

[0126] 1. This disclosure provides the use of induced vesicles in the preparation of an antitumor drug for use in combination with an immunotherapy agent.

[0127] 2. This disclosure provides the use of an immunotherapeutic agent in the preparation of an antitumor drug used in combination with induced vesicles.

[0128] 3. According to the use described in item 1 or 2, the induced vesicle is a vesicle generated by inducing apoptosis of stem cells or somatic cells by external factors when the cells are in normal survival.

[0129] In particular, the induction methods include adding astrocytocin, ultraviolet irradiation, starvation, or thermal stress.

[0130] In particular, the stem cells are selected from mesenchymal stem cells;

[0131] In particular, the mesenchymal stem cells are derived from bone marrow, dental pulp, urine, oral cavity, fat, placenta, umbilical cord, periosteum, tendon, or peripheral blood.

[0132] In particular, the diameter of the induced vesicles is approximately 0.03-10 μm;

[0133] In particular, the diameter of the induced vesicles is approximately 0.03-6 μm;

[0134] In particular, the diameter of the induced vesicles is approximately 0.03-4.5 μm;

[0135] In particular, the diameter of the induced vesicles is approximately 0.03-1 μm;

[0136] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 1–1500 nM;

[0137] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 10–800 nM;

[0138] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 100–800 nM;

[0139] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 200–700 nM;

[0140] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 300–600 nM;

[0141] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 400–600 nM;

[0142] In particular, the time to induce apoptosis by adding astrosporin is approximately 2–24 hours;

[0143] In particular, the time to induce apoptosis by adding astrosporin is approximately 2–15 hours;

[0144] In particular, the time to induce apoptosis by adding astrosporin is approximately 2–10 hours;

[0145] In particular, the induced vesicles showed higher expression of the biomarker Syntaxin 4 than MSCs or exosomes of the same origin;

[0146] In particular, the markers also include one or more of Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5;

[0147] In particular, the induced vesicles are highly expressed by the markers Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5;

[0148] In particular, the expression levels of the markers Annexin V, Flotillin-1, Cadherin 11, and Integrin alpha 5 in the induced vesicles were higher than those in MSCs or exosomes of the same origin.

[0149] In particular, the inducible vesicles are highly expressed by the markers cleaved caspase-3, Calnexin, Calreticulin, CD63, CD9, caspase-3, and CD44;

[0150] In particular, the immunotherapy agent is an immunotherapy drug;

[0151] In particular, the immunotherapeutic agent includes an anti-PD-1 antibody or an anti-PD-L1 antibody;

[0152] In particular, the anti-PD-1 antibody is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, CT-011, AMP-224, MPDL3280A, MEDI4736 or MDX-1105;

[0153] In particular, the anti-PD-L1 antibody is avirumab, durvalumab, or atezolizumab;

[0154] In particular, the tumor is selected from solid tumors or hematologic malignancies;

[0155] In particular, the solid tumor was selected from liver cancer.

[0156] 4. This disclosure provides the use of induced vesicles in the preparation of medicaments for improving or treating poor prognoses in tumor immunotherapy;

[0157] In particular, the induced vesicles are vesicles generated by inducing apoptosis in stem cells or somatic cells when they are in normal survival by adding external factors;

[0158] In particular, the induction methods include adding astrocytocin, ultraviolet irradiation, starvation, or thermal stress.

[0159] In particular, the stem cells are selected from mesenchymal stem cells;

[0160] In particular, the mesenchymal stem cells are derived from bone marrow, dental pulp, urine, oral cavity, fat, placenta, umbilical cord, periosteum, tendon, or peripheral blood.

[0161] In particular, the diameter of the induced vesicles is approximately 0.03-10 μm;

[0162] In particular, the diameter of the induced vesicles is approximately 0.03-6 μm;

[0163] In particular, the diameter of the induced vesicles is approximately 0.03-4.5 μm;

[0164] In particular, the diameter of the induced vesicles is approximately 0.03-1 μm;

[0165] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 1–1500 nM;

[0166] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 10–800 nM;

[0167] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 100–800 nM;

[0168] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 200–700 nM;

[0169] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 300–600 nM;

[0170] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 400–600 nM;

[0171] In particular, the induced vesicles showed higher expression of the biomarker Syntaxin 4 than MSCs or exosomes of the same origin;

[0172] In particular, the markers also include one or more of Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5;

[0173] In particular, the induced vesicles are highly expressed by the markers Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5;

[0174] In particular, the expression levels of the markers Annexin V, Flotillin-1, Cadherin 11, and Integrin alpha 5 in the induced vesicles were higher than those in MSCs or exosomes of the same origin.

[0175] In particular, the inducible vesicles are highly expressed by the markers cleaved caspase-3, Calnexin, Calreticulin, CD63, CD9, caspase-3, and CD44;

[0176] In particular, the tumor immunotherapy is a treatment using anti-PD-1 antibodies or anti-PD-L1 antibodies;

[0177] In particular, the anti-PD-1 antibody is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, CT-011, AMP-224, MPDL3280A, MEDI4736 or MDX-1105;

[0178] In particular, the anti-PD-L1 antibody is avirumab, durvalumab, or atezolizumab;

[0179] In particular, the tumor is selected from solid tumors or hematologic malignancies;

[0180] In particular, the solid tumor was selected from liver cancer.

[0181] 5. This disclosure provides the use of an LDHA detection reagent in extracellular vesicles in the preparation of tumor diagnostic or prognostic reagents or kits;

[0182] In particular, the sources of the extracellular vesicles include blood, serum, plasma, tissue, lysate, extracellular fluid, tissue fluid, lymph, cerebrospinal fluid, aqueous humor, sputum, saliva, urine, or feces;

[0183] In particular, the extracellular vesicle samples were derived from cancer patients;

[0184] In particular, the extracellular vesicles are derived from tumor cells;

[0185] In particular, the detection reagent detects the expression level of the LDHA gene;

[0186] In particular, the detection reagent detects the mRNA expression level of the LDHA gene;

[0187] In particular, the detection reagent detects the protein expression level of the LDHA gene;

[0188] In particular, the detection reagent is selected from at least one of the following groups: quantitative PCR dyes, quantitative PCR primers, quantitative PCR probes, antibodies, functional fragments of antibodies, or conjugated antibodies;

[0189] In particular, the kit is selected from at least one of the following groups: qPCR kit, immunoblotting kit, immunochromatographic kit, flow cytometry kit, immunohistochemistry kit, ELISA kit, or electrochemiluminescence kit.

[0190] In particular, the tumor is a solid tumor or a hematoma;

[0191] In particular, the solid tumor is selected from liver cancer;

[0192] In particular, the method for extracting extracellular vesicles includes the following steps:

[0193] (1) Centrifuge the collected samples for the first time and take the supernatant;

[0194] (2) Centrifuge the supernatant collected in step (1) a second time and take the supernatant;

[0195] (3) Centrifuge the supernatant collected in step (2) for the third time and take the precipitate;

[0196] (4) Wash the precipitate collected in step (3);

[0197] In particular, the first centrifugation is approximately 500-1500g for 5-30 minutes;

[0198] In particular, the second centrifugation is approximately 1000-3000g for 5-30 minutes;

[0199] In particular, the third centrifugation is approximately 10,000-30,000g for 15-60 minutes;

[0200] In particular, the first centrifugation is approximately 600-1500g for 5-30 minutes;

[0201] In particular, the first centrifugation is approximately 600-1000g for 5-30 minutes;

[0202] In particular, the second centrifugation is performed at approximately 1500-3000g for 5-30 minutes;

[0203] In particular, the second centrifugation is performed at approximately 1800-3000g for 5-30 minutes;

[0204] In particular, the third centrifugation is approximately 10,000-20,000g for 15-60 minutes;

[0205] In particular, the third centrifugation is performed at approximately 15,000-20,000 g for 15-60 minutes;

[0206] In particular, the washing process involves adding the precipitate obtained in step (3) to a washing solution, centrifuging at 10,000-30,000 g for 15-60 minutes, and collecting the precipitate to obtain the extracellular vesicles.

[0207] 6. This disclosure provides the application of an LDHA detection reagent in the preparation of prognostic diagnostic reagents or kits for cancer patients after immunotherapy;

[0208] In particular, the test samples for the test reagent include blood, serum, plasma, tissue, lysate, extracellular fluid, tissue fluid, lymph, cerebrospinal fluid, aqueous humor, sputum, saliva, urine, or feces;

[0209] In particular, the test sample for the test reagent is selected from extracellular vesicles;

[0210] In particular, the detection reagent detects the expression level of the LDHA gene;

[0211] In particular, the detection reagent detects the mRNA expression level of the LDHA gene;

[0212] In particular, the detection reagent detects the protein expression level of the LDHA gene;

[0213] In particular, the detection reagent is selected from at least one of the following groups: quantitative PCR dyes, quantitative PCR primers, quantitative PCR probes, antibodies, functional fragments of antibodies, or conjugated antibodies;

[0214] In particular, the kit is selected from at least one of the following groups: qPCR kit, immunoblotting kit, immunochromatographic kit, flow cytometry kit, immunohistochemistry kit, ELISA kit, or electrochemiluminescence kit.

[0215] In particular, the tumor is a solid tumor or a hematoma;

[0216] In particular, the solid tumor was selected from liver cancer.

[0217] 7. This disclosure provides a reagent combination or kit, said reagent combination or kit comprising:

[0218] Extracellular vesicle extraction kit, and

[0219] LDHA detection reagents;

[0220] In particular, the extraction reagent or kit for the extracellular vesicles includes extraction tools or extraction reagents;

[0221] In particular, the extraction tools include blood collection tubes, centrifuge tubes, centrifuges, or pipettes;

[0222] In particular, the extraction reagent includes a buffer solution;

[0223] In particular, the buffer solution includes PBS;

[0224] In particular, the method for extracting extracellular vesicles includes the following steps:

[0225] (1) Centrifuge the collected samples for the first time and take the supernatant;

[0226] (2) Centrifuge the supernatant collected in step (1) a second time and take the supernatant;

[0227] (3) Centrifuge the supernatant collected in step (2) for the third time and take the precipitate;

[0228] (4) Wash the precipitate collected in step (3);

[0229] In particular, the first centrifugation is approximately 500-1500g for 5-30 minutes;

[0230] In particular, the second centrifugation is approximately 1000-3000g for 5-30 minutes;

[0231] In particular, the third centrifugation is approximately 10,000-30,000g for 15-60 minutes;

[0232] In particular, the first centrifugation is approximately 600-1500g for 5-30 minutes;

[0233] In particular, the first centrifugation is approximately 600-1000g for 5-30 minutes;

[0234] In particular, the second centrifugation is performed at approximately 1500-3000g for 5-30 minutes;

[0235] In particular, the second centrifugation is performed at approximately 1800-3000g for 5-30 minutes;

[0236] In particular, the third centrifugation is approximately 10,000-20,000g for 15-60 minutes;

[0237] In particular, the third centrifugation is performed at approximately 15,000-20,000 g for 15-60 minutes;

[0238] In particular, the washing process involves adding the precipitate obtained in step (3) to a washing solution, centrifuging at 10,000-30,000 g for 15-60 minutes, and collecting the precipitate to obtain the extracellular vesicles.

[0239] In particular, the samples include blood, serum, plasma, tissue, lysate, extracellular fluid, tissue fluid, lymph, cerebrospinal fluid, aqueous humor, sputum, saliva, urine, or feces;

[0240] In particular, the reagent is a tumor diagnostic reagent or a prognostic diagnostic reagent for tumor patients after immunotherapy;

[0241] In particular, the tumor is a solid tumor or a hematoma;

[0242] In particular, the solid tumor was selected from liver cancer.

[0243] 8. This disclosure provides the use of the reagent combination or kit according to item 7 in the preparation of tumor diagnostic reagents or kits or prognostic diagnostic reagents or kits for cancer patients after immunotherapy.

[0244] 9. This disclosure provides a pharmaceutical combination for treating tumors, comprising:

[0245] Inducible vesicles, and

[0246] Immunotherapy agents;

[0247] In particular, the drug combination is a pharmaceutical composition or a pharmaceutical kit;

[0248] In particular, the pharmaceutical composition contains a mixture of inducing vesicles and immunotherapeutic agents;

[0249] In particular, the drug kit contains individually packaged inducible vesicles and individually packaged immunotherapy agents;

[0250] In particular, the immunotherapy agent is a treatment using anti-PD-1 antibodies or anti-PD-L1 antibodies;

[0251] In particular, the anti-PD-1 antibody is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, CT-011, AMP-224, MPDL3280A, MEDI4736 or MDX-1105;

[0252] In particular, the anti-PD-L1 antibody is avirumab, durvalumab, or atezolizumab;

[0253] In particular, the tumor is a solid tumor or a hematoma;

[0254] In particular, the solid tumor is selected from liver cancer;

[0255] In particular, the induced vesicles are vesicles generated by inducing apoptosis in stem cells or somatic cells when they are in normal survival by adding external factors;

[0256] In particular, the induction methods include adding astrocytocin, ultraviolet irradiation, starvation, or thermal stress.

[0257] In particular, the stem cells are selected from mesenchymal stem cells;

[0258] In particular, the mesenchymal stem cells are derived from bone marrow, dental pulp, urine, oral cavity, fat, placenta, umbilical cord, periosteum, tendon, or peripheral blood.

[0259] In particular, the diameter of the induced vesicles is approximately 0.03-10 μm;

[0260] In particular, the diameter of the induced vesicles is approximately 0.03-6 μm;

[0261] In particular, the diameter of the induced vesicles is approximately 0.03-4.5 μm;

[0262] In particular, the diameter of the induced vesicles is approximately 0.03-1 μm;

[0263] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 1–1500 nM;

[0264] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 10–800 nM;

[0265] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 100–800 nM;

[0266] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 200–700 nM;

[0267] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 300–600 nM;

[0268] In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 400–600 nM;

[0269] In particular, the time to induce apoptosis by adding astrosporin is approximately 2–24 hours;

[0270] In particular, the time to induce apoptosis by adding astrosporin is approximately 2–15 hours;

[0271] In particular, the time to induce apoptosis by adding astrosporin is approximately 2–10 hours;

[0272] In particular, the induced vesicles showed higher expression of the biomarker Syntaxin 4 than MSCs or exosomes of the same origin;

[0273] In particular, the markers also include one or more of Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5;

[0274] In particular, the induced vesicles are highly expressed by the markers Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5;

[0275] In particular, the expression levels of the markers Annexin V, Flotillin-1, Cadherin 11, and Integrin alpha 5 in the induced vesicles were higher than those in MSCs or exosomes of the same origin.

[0276] In particular, the inducible vesicles are highly expressed by the markers cleaved caspase-3, Calnexin, Calreticulin, CD63, CD9, caspase-3, and CD44.

[0277] 10. This disclosure provides a tumor diagnostic system, the diagnostic system comprising:

[0278] Detection components for LDHA in extracellular vesicles derived from tumor samples, and,

[0279] Result judgment component;

[0280] In particular, the detection component for LDHA in the extracellular vesicles contains the reagent combination or kit described in item 7;

[0281] In particular, the result determination component is used to output the risk of tumor development and / or tumor type based on the LDHA results detected by the detection component in the extracellular vesicles;

[0282] In particular, the disease risk is determined by comparing the detection results of LDHA in extracellular vesicles of the test sample and the normal sample through the result judgment component. When there is a significant or extremely significant difference in LDHA in extracellular vesicles between the test sample and the normal sample, the result judgment component outputs that the test sample has a high risk of developing tumors.

[0283] In particular, the tumor is a solid tumor or a hematoma;

[0284] In particular, the solid tumor was selected from liver cancer.

[0285] 11. This disclosure provides a method for treating tumors, the method comprising administering the pharmaceutical composition of item 9 to a patient in need.

[0286] 12. This disclosure provides a method for diagnosing tumors, the method comprising:

[0287] Using the reagent combination or kit described in item 7, the expression level of LDHA in the extracellular vesicles of the sample to be tested was detected;

[0288] Based on the deviation between the LDHA expression level of extracellular vesicles in the test sample and the LDHA expression level of extracellular vesicles in normal samples, it is determined whether the patient has a tumor or is at risk of developing a tumor.

[0289] In particular, the LDHA expression level refers to the expression level of the LDHA gene, the mRNA expression level of the LDHA gene, or the protein expression level of the LDHA gene.

[0290] In particular, when the cutoff value of LDHA expression level in extracellular vesicles in the test sample is ≥50.2000%, it is determined that the patient has a tumor or is at risk of developing a tumor.

[0291] In particular, the samples to be tested include blood, serum, plasma, tissue, lysate, extracellular fluid, tissue fluid, lymph, cerebrospinal fluid, aqueous humor, sputum, saliva, urine, or feces;

[0292] In particular, the method for extracting extracellular vesicles includes the following steps:

[0293] (1) Centrifuge the collected samples for the first time and take the supernatant;

[0294] (2) Centrifuge the supernatant collected in step (1) a second time and take the supernatant;

[0295] (3) Centrifuge the supernatant collected in step (2) for the third time and take the precipitate;

[0296] (4) Wash the precipitate collected in step (3);

[0297] In particular, the first centrifugation is approximately 500-1500g for 5-30 minutes;

[0298] In particular, the second centrifugation is approximately 1000-3000g for 5-30 minutes;

[0299] In particular, the third centrifugation is approximately 10,000-30,000g for 15-60 minutes;

[0300] In particular, the first centrifugation is approximately 600-1500g for 5-30 minutes;

[0301] In particular, the first centrifugation is approximately 600-1000g for 5-30 minutes;

[0302] In particular, the second centrifugation is performed at approximately 1500-3000g for 5-30 minutes;

[0303] In particular, the second centrifugation is performed at approximately 1800-3000g for 5-30 minutes;

[0304] In particular, the third centrifugation is approximately 10,000-20,000g for 15-60 minutes;

[0305] In particular, the third centrifugation is performed at approximately 15,000-20,000 g for 15-60 minutes;

[0306] In particular, the washing process involves adding the precipitate obtained in step (3) to a washing solution, centrifuging at 10,000-30,000 g for 15-60 minutes, and collecting the precipitate to obtain the extracellular vesicles.

[0307] In particular, the tumor is a solid tumor or a hematoma;

[0308] In particular, the solid tumor was selected from liver cancer. Attached Figure Description

[0309] Figure 1 shows that high glycolysis in HCC is associated with immunosuppressive tumor microenvironment (TME) and tumor apoptosis. (A) Heatmap of glycolysis gene expression levels from the TCGA database, with gene abundance normalized using Z-scores. 371 HCC patients were divided into four groups based on Hallmark glycolysis levels (G1 group n=47, G2 group n=105, G3 group n=130, G4 group n=89). (B) Overall survival analysis of the four glycolysis groups. (C) CIBERSORT analysis of differentially expressed immune cells in the high and low glycolysis groups. (D) Tumor TIDE score analysis of the high and low glycolysis groups. (EG) Comparison of the enrichment of apoptosis- and glycolysis-related genes in HCC samples from the TCGA dataset based on Hallmark glycolysis levels (E), CIBERSORT scores, and M2 cells (F) and Treg cells (G). (H) LDHA mRNA expression in HCC samples from the TCGA database was analyzed based on Hallmark glycolysis levels and CIBERSORT scores of M2 and Treg cells (high glycolysis group n=47, low glycolysis group n=89, high M2-Treg group or low M2-Treg group n=93). (I) Immunohistochemical images of CD206 and Foxp3 in tumor tissues of HCC patients in the control group and PD-1 antibody treatment group. Scale bar, 20 μm. (J) Representative gross photographs of HCC mouse tumor tissues in the control group and PD-1 antibody treatment group. (K) Immunofluorescence images of TUNEL, TGF-β, F4 / 80, and Foxp3 in tumor tissues of HCC patients in the control group and PD-1 antibody treatment group. Scale bar, TUNEL 100 μm, others 20 μm. Experimental data are expressed as mean ± standard deviation (mean ± SD), and graphs and statistical analyses were performed using GraphPad Prism. Analysis between two groups was performed using the independent unpaired Student's t-test; analysis among multiple groups was performed using one-way ANOVA, and pairwise comparisons were conducted using the Tukey test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0310] Figure 2 shows the M2 of HCC. highand Treg high Immunosuppressive features were associated with tumor cell apoptosis and apoptotic vesicles (apoVs). (A) Macrophages, Treg cells, and CD8+ cells in the high-glucose glycolysis group and the low-glucose glycolysis group. + (B) CIBERSORT analysis of T cells. M2 and Treg cells based on CIBERSORT scores, comparing the enrichment of apoptosis and glycolysis-related genes in HCC samples from the TCGA dataset. (C) LDHA mRNA expression in HCC samples from the TCGA database based on Hallmark cell apoptosis levels (high apoptosis group n=48, low apoptosis group n=323). (D) Immunofluorescence images of tumor tissues from HCC patients in the control group and PD-1 antibody treatment group, stained with TUNEL (red), LDHA (green), CD4 and F4 / 80 (pink), and counterstained with Hoechst (blue). Arrows indicate CD4 or F4 / 80 and LDHA double-positive cells. Scale bar, 20 μm. (E) Schematic diagram of PD-1 antibody administration time in orthotopic HCC mice. (J) Western blot analysis of LDHA protein expression in AML-12 and Hepa1-6 cell-derived ApoVs. (KN) Macrophages and CD4 + L-lactate uptake (K and L) and glucose consumption (M and N) by T cells. Macrophages and spleen-derived cells. CD4 + T cells were cultured for 24 hours in either control medium or Hepa 1-6 cell culture supernatant with or without Sup (Hepa 1-6-apoVs), then replaced with low-glucose high-lactate medium (LGHL) and cultured for another 16 hours (n=3). (O and P) macrophages and CD4 + NAD in T cells + / NADH assay (n=4). (Q and R) Flow cytometry analysis of CD86 in macrophages + M1 and CD206 + The positivity rate of M2 (Q) and CD25 + FoxP3 + The positivity rate (R) of Treg cells. Macrophages and spleen-derived cells were cultured in control medium or Hepa1-6 cell culture supernatant, with or without Sup (H-apoVs). CD4 +T cells. All results represent data from at least three independent experiments. Experimental data are presented as mean ± standard deviation (mean ± SD), and graphs and statistical analyses were performed using GraphPad Prism. Independent unpaired Student's t-tests were used for analyses between two groups; one-way ANOVA was used for analyses among multiple groups, and Tukey's test was used for pairwise comparisons. NS, no statistically significant difference. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

[0311] Figure 3 shows the characteristics of apoVs derived from liver cancer cells and their effect on NAD. + The role of metabolism. (A) Nanofluid cytometry analysis and quantification of Annexin V isolated from the plasma of HCC patients in the control group and the PD-1 antibody treatment group. + LDHA in ApoVs + (A) Flow cytometry analysis showing the apoptosis rate of AML-12 and Hepa1-6 cells induced by STS. (C) Isolation process of ApoVs from different cells. (D) Western blot analysis of LDHA protein expression in Ea.hy926 and Hep3B cell-derived ApoVs. (EG) The characteristics of isolated ApoVs were evaluated by SIM, nanoflow cytometry and Western blot, including spherical structure (E), phosphatidylserine (PtdSer) positive staining (F) and expression of ApoV markers cleaved caspase-3, calreticulin and EV marker CD9 (G). (H) Flow cytometry analysis showing the apoptosis rate of macrophages and CD4+ cells. + T cells took up PKH26-labeled Hepa1-6-apoVs. (IL) macrophages (I and J) and CD4 + NAD+ in T cells (K and L) + Measurement of NADH (n=4). Macrophages and spleen-derived macrophages. CD4 + T cells were cultured for 24 hours in either control medium or Hepa1-6 cell culture supernatant with or without Hepa1-6-apoVs (H-apoVs) control, and then replaced with low-glucose high-lactate medium (LGHL) for another 16 hours. Flow cytometry analysis of CD86 in macrophages was performed. + M1 and CD206 + The positivity rate of M2 (M) and CD4 + CD25 in T cells + FoxP3+ The positivity rate of Treg cells (N). Macrophages and spleen-derived cells were cultured using Hepa1-6 cell culture supernatant (Sup). CD4 + T cells were treated with Hepa1-6-apoVs (H-apoVs) or H-apoVs containing an LDH inhibitor (LDHi). All results represent data generated from at least three independent experiments. Experimental data are presented as mean ± standard deviation (mean ± SD) and were plotted and statistically analyzed using GraphPad Prism. Independent unpaired Student's t-tests were used for analyses between two groups; one-way ANOVA was used for analyses among multiple groups, and Tukey's test was used for pairwise comparisons. NS, no statistically significant difference. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0312] Figure 4 shows the characteristics of apoVs derived from mesenchymal stem cells (MSCs) and their metabolic and immunomodulatory effects. (A) Flow cytometry analysis showing the expression of surface markers in MSCs. (B and C) Bright field (B) and TUNEL (green) stained images (C) of MSCs and STS-induced apoptotic MSCs, counterstained with Hoechst (blue). Scale bar, 50 μm. (D) Flow cytometry analysis showing the apoptosis rate of STS-induced MSCs (n=3). (EI) Nanoparticle tracking analysis (NTA), SIM, nanoflow cytometry, and Western blot analysis showed the characteristics of isolated MSC-apoVs: spherical structure with an average size of 221.9 nm, positive staining for PtdSer (Annexin V). + (I) Expression of MSC markers CD44, ApoV markers cleaved caspase-3, calnetin, cadherin, and EV markers CD63 and CD9. (E) NTA showing the average size of ApoVs. (F) Immunofluorescence staining showing positive Annexin V staining. Scale bar, 2 μm. (G and H) Nanoflow cytometry showing the proportions of Annexin V, CD44, CD63, and CD9. (I) Expression of CD44, caspase 3, cleaved caspase 3, calnetin, cadherin, CD63, and CD9 in apoptotic MSCs and MSC-apoVs. (JO) Macrophages (JL) and CD44. + NAD+ in T cells (MO) + NADH and NAD + / NADH assay (n=4). Macrophages and spleen-derived macrophages were cultured in Hepa1-6 cell culture supernatant in the absence of (Sup) or in the presence of MSC-apoVs (M-apoVs) or Hepa1-6-apoVs (H-apoVs). CD4 + T cells. (P) Chemotaxis of Treg cells by macrophages cultured in control medium or Hepa1-6 cell culture supernatant in the absence of (Sup) or presence of MSC-apoVs (M-apoVs) (n=4). Scale bar, 50 μm. (Q) qRT-PCR analysis of CCl22 expression (n=3). Experimental data are expressed as mean ± standard deviation (mean ± SD), and graphs and statistical analyses were performed using GraphPad Prism. Independent unpaired Student's t-test was used for analysis between two groups; one-way ANOVA was used for statistical analysis of results among multiple groups, and Tukey's test was used for pairwise comparisons. NS, no significant difference. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0313] Figure 5 shows that MSC-apoVs reversed the macrophage and CD4+ induced by tumor metabolites. + T cell glycolysis restriction and a predisposition to immunosuppression. (A) Enrichment analysis of upregulated proteins in MSC-apoVs compared to MSC-exosomes via the KEGG pathway. (B) Confocal images showing macrophages and CD4+. + Time-dependent uptake of PKH26-labeled ApoVs (red) by T cells (green), counterstained with Hoechst (blue). Scale bar, 5 μm. (C) Flow cytometry analysis shows macrophages and CD4+. + T cells take up PKH26-labeled ApoVs. (DF) macrophages and CD4 + T cell lactate uptake (D) and glucose consumption (E and F). This is observed in macrophages and spleen-derived cells. CD4 + T cells were cultured in Hepa1-6 cell culture supernatant for 24 hours in the absence of (Sup) or in the presence of MSC-apoVs (M-apoVs) or Hepa 1-6-apoVs (H-apoVs), then replaced with high-lactate, low-glucose medium and cultured for 16 hours (n=3). (G) Western blot analysis of macrophages and CD4+ +Expression levels of p-mTOR, mTOR, p-AMPK, and AMPK in T cells. Flow cytometry analysis (H and I) showed the proportion of CD86-positive M1 and CD206-positive M2 in macrophages (H), CD4+ + CD25 in T cells + FoxP3 + The proportion of Treg cells (I) (n=3). Experimental data are expressed as mean ± standard deviation (mean ± SD), and graphs and statistical analyses were performed using GraphPad Prism. Independent unpaired Student's t-tests were used for analysis between two groups; one-way ANOVA was used for statistical analysis of results among multiple groups, and Tukey's test was used for pairwise comparisons. NS, no statistically significant difference. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0314] Figure 6 shows that systemic infusion of MSC-apoVs inhibited M2 and Treg cells in tumor and peripheral lymphoid tissues, and reduced CD8+ in HCC mice. + T cell infiltration to suppress tumors. (A) Schematic diagram of apoVs infusion time in hepatocellular carcinoma mice. Orthotopic Hepa 1-6 cell-derived hepatocellular carcinoma C57BL / 6 mice were sacrificed after tail vein injection of MSC-apoVs or placebo. (B) Confocal images showing macrophages (green) within the tumor and CD4+ in lymph nodes and spleen. + T cells (green) take up ApoVs (red) and are counterstained with Hoechst (blue). Scale bar: 20 μm for low power field and 5 μm for high power field. (C and D) Flow cytometry analysis shows CD45 in the tumor. + Lin - CD11b + F4 / 80 + CD86 in macrophages + M1 cells (C) and CD206 + The proportion of M2 cells (D) (n=5). (E and F) TNF-α in HCC mouse tumor tissue + F4 / 80 + or TGF-β + F4 / 80 + Immunofluorescence imaging (E) and quantification (F) of double-positive cells. Scale bar, 20 μm. (G) Flow cytometry analysis showed CD25 in the tumor (n=5). + FoxP3 + Treg cells account for 45% of CD45 + CD4 +Percentage of cells. (H) Immunofluorescence images and quantification of Foxp3-positive cells in HCC mouse tumor tissue. Scale bar, 20 μm. (IK) Flow cytometry analysis and quantification of CD45. + CD3 + CD8 + LAG3 in cells + PD-1 + Percentage of exhausted T cells (I) and IFN-γ + Percentage of effector T cells (J) and the ratio of effector / exhausted T cells in the tumor (K) (n=5). (L) Representative images and volumes of orthotopic HCC tumors from each group (n=10). (M) H&E staining of orthotopic hepatocellular carcinoma tumor tissues from each group. Experimental data are expressed as mean ± standard deviation (mean ± SD) and were plotted and statistically analyzed using GraphPad Prism. Independent unpaired Student's t-test was used for analysis between two groups; one-way ANOVA was used for statistical analysis of results among multiple groups, and Tukey's test was used for pairwise comparisons. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0315] Figure 7 shows the biodistribution of MSC-apoVs in different organs and images of the livers of HCC mice treated with MSC-apoVs. (AC) IVIS images show that tumors (A), lymph nodes (B), and spleen (C) of HCC mice took up ApoVs after tail vein injection of MSC-apoVs. (D and E) Gating strategies of M1 and M2 macrophages (D) and Treg cells (E). (F and G) Flow cytometry analysis shows CD45 in lymph nodes (F) and spleen (G) (n=4). + CD4 + CD25 + FoxP3 + Percentage of Treg cells. (H) Flow cytometry analysis showed CD45 + CD3 + CD8 in cells + Percentage of T cells (n=3). (I) Images of orthotopic liver cancer tumors in each group (n=10). (JL) NAD+ in tumor immune cells of tumor-bearing mice treated with MSC-apoVs. + NADH and NAD +NADH assay (n=3). LDH activity assay in tumor immune cells (M) (n=5) and lymph nodes (N) (n=6). Tumor immune cells (monocytes and lymphocytes) were isolated using a mouse tumor tissue infiltrating mononuclear cell isolation kit. Experimental data are expressed as mean ± standard deviation (mean ± SD), and graphs and statistical analyses were performed using GraphPad Prism. Independent unpaired Student's t-test was used for analysis between two groups; one-way ANOVA was used for statistical analysis of results among multiple groups, and Tukey's test was used for pairwise comparisons. NS, no significant difference. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0316] Figure 8 shows that miR-34c-5p contributes to MSC-apoVs-mediated LDHA inhibition, thereby reversing the immune phenotype. (A and B) Western blot analysis shows macrophages (A) and CD4+. + LDHA, HK1, PFKL, and PKM2 proteins were expressed in T cells (B). Macrophages and spleen-derived macrophages were cultured in Hepa 1-6 cell culture supernatant with or without MSC-apoVs. CD4 + T cells. (C) qRT-PCR analysis showed that the levels of miR-34a-5p, miR-34c-5p, miR-491-3p, miR-501-3p, and miR-3069-5p in macrophages increased only after ApoV treatment (n=3). (D and E) Western blot analysis showed that after MSC apoV or anti-miR-34c-5papoV treatment, the levels of macrophages (D) and CD4+ increased. + Protein expression of LDHA in T cells (E). (FJ) Flow cytometry analysis of the proportion of CD86-positive M1 and CD206-positive M2 in macrophages (FH) and CD4+. + CD25 in T cells + FoxP3 + The proportion of Treg cells (I and J) (n = 3). (KM) Macrophage NAD + NADH and NAD + / NADH assay. Macrophages and spleen-derived cells were cultured using Hepa 1-6 cell culture supernatant. CD4 +T cells were treated with MSC-apoVs or miR-34c-5p-deficient MSC-apoVs. (N) Schematic diagram of how ApoVs inhibit LDHA-mediated inhibition of immune cell glycolysis. Abbreviations are as follows: Sup, Hepa 1-6 cell culture supernatant; apoVs, MSC-apoVs; anti-miR-apoVs, i.e., miR-34c-5p-deficient apoVs isolated from miR-34c-5psiRNA-treated MSCs. Experimental data are expressed as mean ± standard deviation (mean ± SD) and were plotted and statistically analyzed using GraphPad Prism. Independent unpaired Student's t-test was used for analysis between two groups; one-way ANOVA was used for statistical analysis of results among multiple groups, and Tukey's test was used for pairwise comparisons. NS, no significant difference. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0317] Figure 9 shows the expression of miR-34c-5p in apoVs and the validation of NAMPT knockout. (A) Five miRNAs predicted by DIANA and Targetscan to potentially target LDHA gene expression. (B) NAMPT expression was detected by Western blot after MSCs were transfected with three siRNA sequences targeting NAMPT for 48 h. (C) qRT-PCR analysis of miR-34c-5p in MSCs and Hepa 1-6 derived ApoVs (n=3). (D) Western blot analysis of LDHA, NMRK1, and NAMPT expression levels in MSCs and Hepa 1-6 derived ApoVs. (E) Overall survival determination of patients with high LDHA and high glycolytic HCC with different hsa-miR-34c-5p expression levels in the TCGA database (n=74). (F and G) Western blot analysis of macrophages (F) and CD4+. + Expression levels of NMRK1, NAMPT, HK1, PFKL, and PKM2 in T cells (G). BMDM and spleen-derived cells were cultured in control medium or Hepa 1-6 cell culture supernatant, with or without Sup (M-apoVs) or with Hepa 1-6-apoVs (H-apoVs). CD4 +T cells. Experimental data are expressed as mean ± standard deviation (mean ± SD), and graphs and statistical analyses were performed using GraphPad Prism. Independent unpaired Student's t-tests were used for analyses between two groups; one-way ANOVA was used for analyses among multiple groups, and Tukey's test was used for pairwise comparisons. ****P < 0.0001.

[0318] Figure 10 shows that MSC-apoVs transport of NAMPT promotes NAD. + Anabolic glycolysis of immune cells. (A) Heatmap shows that, compared with MSC-exo, proteomics analysis based on MSC-apoVs shows that NAMRK1 and NAMPT are enriched in MSC-apoVs. (B and C) Western blot analysis shows macrophages (B) and CD4 + NMRK1 and NAMPT proteins are expressed in T cells (C). Macrophages and spleen-derived macrophages were cultured in Hepa1-6 cell culture supernatant with or without MSC-apoVs. CD4 + T cells. (D and E) Western blot analysis showed that macrophages (D) and CD4+ were significantly increased after treatment with MSC-apoVs or NAMPT KD-apoVs. + NAMPT protein expression in T cells (E). Flow cytometry analysis of the positivity rates of CD86-M1 and CD206-M2 in macrophages (FH) and CD4. + CD25 in T cells + FoxP3 + Positive rates of Treg cells (I and J) (n = 3). (KM) Macrophage NAD + NADH and NAD + / NADH assay. Macrophages and spleen-derived cells were cultured using Hepa 1-6 cell culture supernatant. CD4 + T cells were treated with MSC-apoVs or NAMPT KD-apoVs. (N) How do ApoVs promote NAD+? +A schematic diagram of immune cell glycolysis initiated by anabolism. Abbreviations are as follows: cSup, Hepa 1-6 cell culture supernatant; apoVs, MSC-apoVs; NAMPT KD-apoVs, NAMPT-deficient apoVs isolated from NAMPT siRNA-treated MSCs. Experimental data are expressed as mean ± standard deviation (mean ± SD), and graphs and statistical analyses were performed using GraphPad Prism. Independent unpaired Student's t-test was used for analysis between two groups; one-way ANOVA was used for statistical analysis of results among multiple groups, and Tukey's test was used for pairwise comparisons. NS, no significant difference. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

[0319] Figure 11 shows that systemic infusion of MSC-apoVs eliminated immunosuppressive tumor microenvironment (TME), enhanced anti-tumor immunity, and promoted the therapeutic effect of anti-PD-1 therapy in HCC mice. (A) Schematic diagram of the administration time of ApoVs and PD-1 antibodies in hepatocellular carcinoma mice. C57BL / 6 mice with orthotopic Hepa1-6 cell-derived hepatocellular carcinoma received MSC-apoVs and anti-PD-1 alone or in combination. (BD) Flow cytometry analysis showed LAG3 in the tumor. + PD-1 + Exhausted T cells (B) and IFN-γ + Effector T cells (C) account for 5% of CD45 + CD3 + CD8 + Percentage of cells, and effector CD8 + / Proportion of exhausted T cells (D) (n=5). (E) Flow cytometry analysis showed CD25 in the tumor + FoxP3 + Treg cells account for 45% of CD45 + CD4 + Percentage of cells (n=5). (F) Immunofluorescence image of FoxP3-positive cells in orthotopic hepatocellular carcinoma tumor. Scale bar, 20 μm. (G) Treg cells / effect CD8 cells in tumor. + The proportion of T cells (n=5). Flow cytometry analysis (H and J) showed CD45 in the tumor. + Lin - CD11b + F4 / 80 + CD86 in macrophages + M1 cells (H) and CD206 + Percentage of M2 cells (J) (n=5). TNF-α in in situ hepatocellular carcinoma tumors (I and K).+ F4 / 80 + or TGF-β + F4 / 80 + Immunofluorescence images of double-positive cells. Scale bar, 20 μm. (L) Ratio of M2 macrophages to M1 macrophages in tumors (n=5). (M) Images and volumes of orthotopic hepatocellular carcinoma tumors in each group (n=5). (N) H&E staining of orthotopic hepatocellular carcinoma tumors in each group. Experimental data are expressed as mean ± standard deviation (mean ± SD), and graphs and statistical analyses were performed using GraphPad Prism. Independent unpaired Student's t-test was used for analysis between two groups; one-way ANOVA was used for statistical analysis of results among multiple groups, and Tukey's test was used for pairwise comparisons. NS, no significant difference. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0320] Figure 12 shows that combined treatment with MSC-apoVs and anti-PD1 inhibits tumor growth in HCC mice. (A) Flow cytometry analysis shows CD4 in the spleen of mice with orthotopic hepatocellular carcinoma. + and CD8 + T cells account for 45% of CD45 + CD3 + Percentage of cells (n=5). (BD) Flow cytometry analysis showed that CD25 was present in lymph nodes and spleen of mice with orthotopic hepatocellular carcinoma. + FoxP3 + Treg cells account for 45% of CD45 + CD4 + Percentage of cells (n=5). (E) Quantification of Foxp3-positive cells in orthotopic hepatocellular carcinoma tumors. (F) Gating strategy for M1 and M2 macrophage analysis. (G and H) THF-α in orthotopic liver tumors. + F4 / 80 + or TGF-β + F4 / 80 +Proportion of double-positive cells. (I) Images of orthotopic hepatocellular carcinoma tumors in each group (n=5). (J and K) Immunofluorescence images of orthotopic hepatocellular carcinoma tumors and the proportion of TUNEL(J) and ki67(K) positive cells. Scale bar, TUNEL staining 100μm, ki67 staining 20μm. Experimental data are expressed as mean ± standard deviation (mean ± SD), and graphs and statistical analyses were performed using GraphPad Prism. Independent unpaired Student's t-test was used for analysis between two groups; one-way ANOVA was used for statistical analysis of results among multiple groups, and Tukey's test was used for pairwise comparisons. NS, no significant difference. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0321] Figure 13 shows the metabolism of tumor-infiltrating immune cells in orthotopic hepatocellular carcinoma mice treated with anti-PD-1 and rebalancing by MSC-apoVs. (AC) NAD+ in tumor immune cells of orthotopic HCC mice treated with MSC-apoVs and anti-PD-1 monotherapy or combination therapy. + NADH and NAD + / NADH assay (n=3). (D and E) Determination of LDH activity in immune cells from different tumor tissues (D) (n=5) and lymph nodes (E) (n=6). Tumor immune cells (monocytes and lymphocytes) were isolated using a mouse tumor tissue infiltrating mononuclear cell isolation kit. (F) qRT-PCR analysis showing the expression of miR-34c-5p in each group of tumor tissues (n=4). (G and H) F4 / 80 in each group of tumor tissues + Macrophages (G) or CD4 + Immunofluorescence images and proportions of high-density NAMPT cells in T cells (H). Scale bar, 20 μm. Experimental data are expressed as mean ± standard deviation (mean ± SD), and graphs and statistical analyses were performed using GraphPad Prism. Independent unpaired Student's t-test was used for analysis between two groups; one-way ANOVA was used for statistical analysis of results among multiple groups, and Tukey's test was used for pairwise comparisons. NS, no significant difference. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

[0322] Figure 14 shows the flowchart of the separation and characterization of human blood EVs.

[0323] Figure 15 shows LDHA in human blood samples. + AV + Assessment of the proportion of apoVs in the diagnosis of liver cancer. (A) LDHA levels in blood samples from different subjects. +AV + (B) ROC curve analysis for diagnosing liver cancer. AFP (Alpha-Fetoprotein) value refers to the concentration level of alpha-fetoprotein in the blood circulation. NS, no significant difference. ****P < 0.0001.

[0324] Figure 16 shows AFP and LDHA in human blood samples. + AV + Correlation analysis of the proportion of apoVs and the size of liver cancer. (A) Scatter plot of correlation between human blood AFP levels and tumor diameter. (B) LDHA + AV + Scatter plot showing the correlation between the proportion of apoVs and tumor diameter. Detailed Implementation

[0325] The following specific embodiments further illustrate the technical solutions of this disclosure. These specific embodiments do not represent a limitation on the scope of protection of this disclosure. Any non-essential modifications and adjustments made by others based on the concept of this disclosure still fall within the scope of protection of this disclosure.

[0326] The terms “comprising” or “including” are intended to indicate that a composition (e.g., a medium) and a method include the listed elements, but do not exclude other elements. When used to define compositions and methods, “consistently of” means excluding other elements that are of any significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements defined herein does not exclude other materials or steps that do not materially affect the essential and novel features of the claimed application. “Constitutes of” means excluding trace elements and substantial method steps that are other components. Embodiments defined by each of these transitional terms are within the scope of this application. The term “and / or” as used herein refers to and covers any and all possible combinations of one or more of the associated listed items. When used in a list of two or more items, the term “and / or” means that any one of the listed items may be used alone, or any combination of two or more of the listed items may be used. For example, if a composition, combination, structure, etc., is described as comprising (or containing) components A, B, C, and / or D, then the composition may contain A alone; contain B alone; contain C alone; contain D alone; contain a combination of A and B; contain a combination of A and C; contain a combination of A and D; contain a combination of B and C; contain a combination of B and D; contain a combination of C and D; contain a combination of A, B, and C; contain a combination of A, B, and D; contain a combination of A, C, and D; contain a combination of B, C, and D; or use a combination of A, B, C, and D. STS in this disclosure refers to asteroides.

[0327] In this document, "ApoV" is synonymous with "ApoVs," "apoVs," "MSC-ApoV," or "mesenchymal stem cell-ApoV," referring to "inducible vesicles," also known as IEVs. In this disclosure, IEVs is an abbreviation for induced vesicles, and can be referred to as induced vesicles or induced extracellular vesicles (IEVs). Induced extracellular vesicles refer to a type of subcellular product produced when precursor cells (e.g., stem cells) are normally viable and are induced to apoptosis. These subcellular products typically have a membrane structure, express apoptosis markers, and some contain genetic material (DNA). The inventors have discovered that induced extracellular vesicles are a distinct class of substances from cells and conventional extracellular vesicles (such as exosomes). In some embodiments, the normally viable cells are, for example, non-apoptotic cells, non-senescent cells, non-aged cells with arrested proliferation, non-cryopreserved cells, non-malignant cells with abnormal proliferation, or non-damaged cells. In some embodiments, the normally viable cells are taken from cells at 80-100% contact fusion during cell culture. In some embodiments, the normally viable cells are taken from cells in the logarithmic growth phase. In some embodiments, the normally viable cells are taken from primary cultured and passaged cells derived from human or mouse tissue. In some embodiments, the normally viable cells are taken from established cell lines or cell strains. In some embodiments, the precursor cells are taken from early-stage cells.

[0328] In this disclosure, STS stands for astrosporin. In this document, LN refers to "lymph node". In this document, LT refers to "lymphatic tissue". In the embodiments described herein, MSCs used are adipose-derived mesenchymal stem cells.

[0329] Materials and methods

[0330] Human samples

[0331] Tumor tissues (n=16) were obtained from HCC patients who underwent hepatectomy between April 2022 and March 2023 and were divided into two groups. Group 1 samples were obtained from patients treated with α-PD-1 antibody (200 mg, every 3 weeks, intravenously) (n=8), and Group 2 samples were obtained from patients who did not receive immunotherapy (n=8). Patient data are detailed in Table 1. Human tumor tissues were analyzed according to safety guidelines and coated with paraffin.

[0332] Blood samples were collected from HCC patients (n=5) and age-matched control subjects (n=5) in BD Vacutainer. TM The blood was collected in EDTA tubes and processed within 2 hours of blood collection. Plasma was prepared from the blood by centrifugation at 800g for 10 minutes at 4°C, followed by centrifugation at 2000g for 10 minutes at 4°C, collecting the supernatant again. The plasma was then centrifuged at 16000g for 30 minutes at 4°C, collecting the precipitate to separate circulating apoVs, and then washed once with 0.1μm filtered PBS (16000g, 30 minutes).

[0333] This study was conducted in accordance with ethical guidelines for human samples. The experimental protocol was reviewed by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University and complies with the relevant regulations on human welfare ethics of the Third Affiliated Hospital of Sun Yat-sen University (Approval No.: Zhongda Fusan Yilun II 2023-261-01).

[0334] Table 1. Patient information in the PD-1 antibody treatment group and the blank control group.

[0335] TCGA Database Analysis

[0336] RNA sequencing expression profiles and corresponding clinical information of 371 hepatocellular carcinoma samples were downloaded from the TCGA dataset. Cluster analysis was performed on the heatmap based on the HALLMARK_GLYCOLYSIS gene set using the R software package pheatmap (v1.0.12), resulting in four clusters. Genes with a SD > 0.1 were retained in the gene expression heatmap. If the number of input genes exceeded 1000, the top 25% of genes were extracted after sorting by SD. The Kaplan-Meier method was used to analyze the survival of different groups of TCGA samples. Log-rank test and univariate Cox proportional hazards regression were used to generate p-values ​​and 95% confidence intervals for hazard ratios (HR). HR represents the hazard ratio of low-expression samples relative to high-expression samples. HR > 1 indicates that the gene is a risk factor, and HR < 1 indicates that the gene is a protective factor. The predictive accuracy of a specific mRNA was compared using timeROC (v 0.4). A higher AUC value indicates stronger predictive ability. All analytical methods and R language packages used were R (foundation for statistical computing 2020) version 4.0.3, ggplot2 (v3.3.3), and ggpubr (0.4.0). The CIBERSORT algorithm (Newman, AM, et al. (2015); Chen, B., et al. (2018)) was used to evaluate the immune scores of the TCGA database for liver cancer. The Tumor Immune Dysfunction and Exclusion algorithm (TIDE score) was used to predict the potential ICB response in different groups (Jiang, P., et al. (2018)), and lactate dehydrogenase A (LDHA) gene expression was analyzed based on the enrichment level of Hallmark apoptosis genes. For gene set enrichment analysis (GSEA), TCGA samples were divided into two groups based on Hallmark glycolysis, Hallmark apoptosis gene enrichment levels, and the levels of M2 and Treg (CIBERSORT score). Based on gene expression profiles and phenotypic groupings, the MSigDB h.all.v7.4.symbols.gmt dataset was used to evaluate related pathways and molecular mechanisms. The minimum gene set was set to 5, the maximum gene set to 5000, and 1000 resamplings were performed. An FDR < 0.25 was considered statistically significant.

[0337] Constructing a mouse model of liver cancer

[0338] This experiment used the Hepa 1-6 mouse liver cancer cell line as a mouse model for hepatocellular carcinoma (HCC) through orthotopic liver injection. Male C57BL / 6 wild-type mice (5-6 weeks old) were purchased from GemPharmatech. All animal experiments complied with the ethics committee of Sun Yat-sen University (SYSU-IACUC-2023-001858). Mice were fed and watered in a dark-light cycle environment of 22±2℃, 55±10% humidity, and 12 hours. Mice underwent a one-week acclimatization period before experimental use. Mice were anesthetized with isoflurane (2%). After adequate anesthesia, the abdominal hair was shaved with an electric razor, the abdomen was disinfected with iodine, and a longitudinal abdominal incision was made with a sterile scalpel to expose the liver. The liver was then injected with 1×10⁻⁶ HCC. 6 A mixture of DMEM and Matrigel (1:1 ratio, Matrigel, 354234, Corning) of Hepa1-6 cells was injected into the left lobe of the liver of C57BL / 6j mice to establish an in situ HCC model.

[0339] Hepa1-6-apoVs exacerbated liver cancer in mice.

[0340] Before treatment, HCC mice participating in the experiment were randomly divided into two groups of four. One week after modeling, mice were injected intravenously via the tail vein with a suspension of Hepa 1-6-apoVs in PBS containing 10% heparin at a dose of 1×10⁻⁶. 10 One Hepa 1-6-apoVs / animal. Injected every 3 days. The control group received a homologous treatment of PBS suspension containing an equal volume of 10% heparin.

[0341] PD-1 monoclonal antibody treatment of liver cancer mice

[0342] For an in vivo study of PD-1 monoclonal antibody therapy for liver cancer, HCC mice were randomly divided into two groups of five mice each before treatment. Mice received intraperitoneal injection of the α-PD-1 antibody RMP1-14 (BE0146, BioXCell) at a dose of 10 mg / kg every 3 days. The control group received isotype-modified rat IgG 2a monoclonal antibody (BE0089, BioXCell). At the end of the experiment, mice were sacrificed to collect tumor, spleen, and lymph node (LN) samples for further analysis. The modified elliptic formula V = 1 / 2 (length × width) was used. 2 Calculate tumor volume.

[0343] For the isolation of apoVs derived from tumor tissue: Tumor tissue from orthotopic HCC model mice was minced with scissors and digested with type I collagenase (2 mg / ml, LS004196, Worthington-Biochem) in serum-free medium. Digestion was carried out with stirring at 37°C for 60 minutes, followed by centrifugation at 800g for 10 minutes, and then centrifugation at 4°C, 2000g for 10 minutes to remove cell debris. Finally, the supernatant was centrifuged at 4°C, 16000g for 30 minutes to separate apoVs, and then washed once with 0.1 μm filtered PBS (16000g, 30 min). The resulting precipitate was the hepatocellular carcinoma tissue apoVs.

[0344] Cell isolation and culture

[0345] (1) Hephe1-6 cell line, Hep3B cell line and Ea.Hy926 cell line

[0346] The mouse hepatocellular carcinoma cell line Hephe1-6, the human hepatocellular carcinoma cell line Hep3B, and the human endothelial cell line Ea.Hy926 were purchased from the American Type Culture Collection (ATCC CRL-1830, Manassas, VA) and cultured in high-glucose DMEM medium (BL304A, Biosharp) containing 15% fetal bovine serum (FBS, FSP500, ExCell Bio) and 1% penicillin / streptomycin (P / S, 15140163, Invitrogen). The mouse hepatocyte cell line AML-12, purchased from Procell Life Science and Technology, was cultured in DMEM / F12 (BL305A, Biosharp) containing 10% FBS, 10 μg / ml insulin, 5.5 μg / ml transferrin, 5 ng / ml selenite (ITS, ITSS-10201, OriCell), 40 ng / ml dexamethasone (D4902, Sigma), and 1% P / S. An orthotopic tumor model was established using the Hepa1-6 cell line.

[0347] (2) Fat-derived MSCs

[0348] Fat-derived MSCs were isolated according to a previously reported protocol (Gimble, JM, et al. (2007)). Subcutaneous white adipose tissue from the mouse inguinal region was rinsed with PBS containing 1% P / S, minced, and digested in serum-free α-MEM medium with 2 mg / ml type I collagenase (LS004196, Worthington-Biochem) and 4 mg / ml type II dispersin (4942078001, Sigma) at 37°C for 60 minutes at 180 rpm. Digestion was then terminated with an equal volume of α-MEM containing 10% FBS. Centrifuge at 2000 rpm for 5 minutes, pass cells through a 70 μm filter (15-1070, Biologix) to obtain a single-cell suspension of adipose-derived mesenchymal stem cells (ADSCs), and seed them in 10 cm culture dishes (TCD010100, Biofil) and culture in complete medium (α-MEM supplemented with 20% FBS, 2 mM GlutaMAX (35050061, Invitrogen), 55 μM 2-mercaptoethanol (21985023, Invitrogen) and 1% P / S) at 37°C and 5% CO2.

[0349] (3) Macrophages derived from bone marrow

[0350] Bone marrow-derived macrophages (BMDMs) were isolated from the femur and tibia of C57BL / 6 mice for macrophage induction. After euthanizing 6-8 week old mice, the femur was isolated, and muscle and connective tissue were aseptically dissected to expose the bone marrow cavity. The bone marrow tissue was flushed out using basal PBS. The bone marrow cell suspension was then filtered through a 70 μm pore size cell filter to remove impurities and transferred to centrifuge tubes. The cells were centrifuged at 1500 rpm for 5 minutes and then resuspended in α-MEM complete medium. Next, the cell suspension was seeded into 6 cm cell culture dishes and incubated at 37°C with 5% CO2 for 24 hours. Non-adherent cells from the supernatant were then collected, centrifuged at 15,000 rpm for 5 minutes, and resuspended in DMEM complete medium containing 10% FBS, 1% P / S, and 30 ng / ml recombinant mouse macrophage colony-stimulating factor (M-CSF) (315-02, PeproTech). The cells were then seeded into 24-well plates, with half the culture medium replaced every other day for a total of 7 days. Mouse bone marrow-derived macrophages were then used for subsequent experiments after 7 days.

[0351] (4) Mice CD4 + T cells

[0352] Use EasySep according to the manufacturer's instructions. TM mice CD4 + T-cell isolation kit (19765, stem cells), used to isolate mouse spleen cells. CD4 + T cells. CD4 + T cells were cultured in RPMI 1640 medium (BL303A, Biosharp) containing 10% FBS and 1% P / S, and then cultured for 3 days in tumor-conditioned medium or Treg-conditioned medium in culture plates conjugated with anti-CD3 and anti-CD28 antibodies (2 μg / ml each, BD Bioscience): IL-2 (50 U / ml, 212-12, PeproTech) and human TGF-β1 (20 ng / ml, 7754-BH-005, R&D Systems). Hepa1-6 cells were cultured in RPMI 1640 for 24 hours to obtain tumor culture medium. The conditioned medium (CM) contained 5% Hepa1-6 medium and 95% of the corresponding RPM11640 medium.

[0353] Isolation and characterization of apoVs

[0354] To induce apoptosis, cells were washed twice with 0.1 μM filtered PBS (C10010500BT, ThermoFisher). 5 ml of α-MEM containing STS (250 nM, for mesenchymal stem cells, ALX-380-014-M005, Enzo Life Sciences) or 5 ml of DMEM containing STS (1000 nm, for Hepa1-6, Hep3B, Ea.hy926, and AML-12) was added to the culture dish to induce apoptosis for 6 hours. The supernatant was then collected and centrifuged at 800 g and 2000 g for 10 minutes at 4 °C to remove cell debris. Subsequently, the supernatant was centrifuged at 16000 g for 30 minutes at 4 °C to separate apoVs, followed by washing the apoVs once with 0.1 μM filtered PBS (16000 g, 30 minutes).

[0355] Subsequently, apoVs were stained with CellMask Deep Red Plasma Membrane Stain (C10046, ThermoFisher) at 37°C for 5 minutes, and then stained with FITC Annexin V (556419, BD Biosciences) in 1×Annexin V binding buffer (556454, BD Pharmingen) at 4°C for 15 minutes. They were then observed using an Elyra 7 Lattice SIM (Zeiss, Germany). The expression rates of vesicle markers and the total EV value produced by apoptotic cells were determined using NanoFCM (U30, China). Proteomic analysis of MSC-apoVs and mesenchymal stem cell-derived exosomes was used to analyze NAD+. + KEGG pathway enrichment analysis and heatmap analysis were performed on rescue pathway-related proteins (Zhang, X., et al. (2022)).

[0356] Flow cytometry detection and analysis

[0357] Apoptosis rate detection of AML-12 and Hepa1-6 cells

[0358] To detect the apoptosis rate, Hepa1-6 cells and AML-12 cells were co-incubated at 4°C for 15 minutes with 1×Annexin V binding buffer (556454, BD Biosciences) containing FITC Annexin V (556419, BD Biosciences) and 7AAD probe (559925, BD Biosciences). The apoptosis rate was calculated by flow cytometry (NovoCyte, ACEA, USA) within 30 minutes.

[0359] Detection of immune cells in tumors, spleen and lymph nodes

[0360] Tumors, spleens, and draining lymph nodes were collected, and immune cells were isolated. Macrophages were stained with FITC-CD93 (early B cell line) (AA4.1, 136507, Biolegend), APC-Cy7-CD45 (30-F11, 103116, Biolegend), BV510-CD11b (M1 / 70, 101263, Biolegend), APC-F4 / 80 (BM8, 123116, Biolegend), PE-CD206 (MMR) (C068C2, 141706, Biolegend), and PerCP-Cy5.5-CD86 (GL-1, 10528, Biolegend) at 4°C for 30 minutes. Tregs were stained with Pacific Blue-CD45 antibody (30-F11, 103126, Biolegend), APC-CD4 (RM4-5, 100516, Biolegend), PEFoxp3 (150D, 320008, Biolegend), and FITC-CD25 (PC45, 102006, Fo61). APC for T cells Cy7-CD45 (30-F11, 103116, Biolegend), FITC-CD3 (145-2C11, 100306, Biolegend), BV421-CD8 (53-6.7, 100738, Biolegend), PE-CD29 7 (PD-1) (29F.1A12, 135206, Biolegend), BV785-CD223 (LAG3) (C9B7W, 125219, Biolegend) and APC-IFNγ (XMG1.2, 505810, Biolegend) staining. Lymphocytes were stained with Pacific Blue-CD45 (30-F11, 103126, Biolegend), PE-CD3 (17A2, 100206, Biolegend), FITC-B220 (RA3-6B2, 103206, Biolegend), APC-CD8 (53-6.7, 100712, Biolegend), and PerCP-Cy5.5-CD4 (RM4-4, 116012, Biolegend).

[0361] Cellular uptake of apoVs

[0362] apoVs were labeled with PKH26 (MINI26, Sigma). The apoVs were then separated by centrifugation and washed twice with PBS to further remove unbound PKH26. Macrophages or CD4 cells incubated with the PKH26-labeled apoVs were fixed with 4% PFA.+ T cells were blocked at room temperature and incubated with either anti-F4 / 80 antibody (ab6640, Abcam) or anti-CD4 antibody (100516, Biolegend). Cells were then incubated with either anti-rat secondary antibody 488 (A11006, Invitrogen) or anti-rat secondary antibody 647 (A21247, Invitrogen) and the nuclei were counterstained with Hoechst 33342 (H3570, Invitrogen). Fluorescence imaging was performed using a confocal microscope (LSM 980, Zeiss, Germany) and analyzed using ImageJ software. Additionally, macrophages or CD4 cells treated with PKH26-labeled apoVs were also analyzed. + T cells were analyzed by flow cytometry.

[0363] Cellular uptake of apoVs

[0364] PKH26-labeled apoVs were intravenously injected into C57BL / 6 mice with orthotopic tumors. The harvested organs were imaged using IVIS spectroscopy (PerkinElmer) to assess the biodistribution of apoVs. Fluorescence intensity was quantitatively analyzed using Living Image software (PerkinElmer). Organs were then fixed in 4% paraformaldehyde (PFA), cryoprotected with 30% sucrose, and embedded in an optimal cutting temperature (OCT) compound (4583, SAKURA). 6 μm frozen sections were then prepared (CM1950, Leica). Further observation of macrophages and CD4+ was conducted. + T cell uptake of apoVs in vivo, F4 / 80 and CD4 staining, as described above. Images were taken using a confocal microscope (LSM 980, Zeiss) and analyzed using ImageJ software.

[0365] miRNA inhibitors and small interfering RNA (siRNA) transfection

[0366] To inhibit miR-34c-5p, Lipofectamine was used. TM MSCs were transfected using RNAiMAX transfection reagent (13778075, Thermo Fisher) and miR-34c-5p inhibitor (RiboBio, China) according to the manufacturer's instructions. A non-targeted miRNA inhibitor was used as a negative control.

[0367] To knock out NAMPT, Lipofectamine was used. TM NAMPT-siRNA was transfected using RNAiMAX transfection reagent (RiboBio, China). A non-targeted control siRNA (RiboBio, China) was used as a negative control. Transfection efficiency was verified using Western blot 48 hours post-transfection.

[0368] RNA isolation and qRT-PCR

[0369] Total RNA was extracted using Trizol reagent (15596018, Invitrogen). For qRT-PCR of mRNA, cDNA was synthesized using the PrimeScript RT kit (RR037A, Takara). qRT-PCR was then performed using SYBR Green Master Mix (Q711-03, Vazyme) and gene-specific primers. GAPDH was used as an internal control, and 2... -ΔΔCT The relative expression level of each gene was calculated for quantification. Values ​​are expressed as fold changes. For qRT-PCR of miRNAs, cDNA was synthesized using the PrimeScript RT kit and stem-loop RT primers, and qRT-PCR was performed using SYBR Green Master Mix, miRNA-specific forward primers, and universal reverse primers. All primer sequences are shown in Table 2.

[0370] Table 2 Primers for real-time quantitative polymerase chain reaction (qRT-PCR)

[0371] Glucose, L-lactic acid, lactate dehydrogenase (LDH) activity, NAD + and NADH determination

[0372] Glucose was measured using a glucose assay kit (BC2505, Solarbio), and L-lactic acid was measured using a lactate assay kit (BC2235, Solarbio). LDH activity in tumor immune cells and lymph nodes isolated from orthotopic tumor C57BL / 6 mice (n=4-6 per group) was measured using a lactate dehydrogenase (LDH) activity assay kit (BC0685, Solarbio) according to the manufacturer's instructions. NAD+ was used. + The NADH quantitative kit (S0175, Beyotime) was used to measure tumor immune cells, lymph nodes, macrophages, and CD4+ isolated from orthotopic tumor C57BL / 6 mice (4-6 per group). +NAD and NADH in T cells. Tumor immune cells (monocytes and lymphocytes) were isolated using a mouse tumor tissue infiltrating mononuclear cell isolation kit (P9000, Solarbio).

[0373] Histological and immunofluorescence staining

[0374] HCC mouse tumor tissue was fixed with 4% PFA for 24 hours. Paraffin-embedded sections (6 μm) were prepared for H&E staining. Images were obtained using an optical microscope (Zeiss, Germany). Frozen sections of air-dried tissue samples were permeabilized with 0.3% Triton X-100 (X100, Sigma) for 15 min, blocked with 5% BSA (GC305010, Serviceebio) for 60 min, and incubated overnight at 4°C with the following primary antibodies: anti-F4 / 80 (Ab6640, Abcam), anti-CD4 (100516, Biolegend), anti-ki67 (AF0198, Affinity), anti-TNF-α (11969S, CST), anti-TGF-β (A16640, Abclonal), anti-Foxp3 (Ab215206, Abcam), and anti-NAMPT (A22044, Abclock). After incubation with the primary antibody, sections were washed three times with PBS and incubated for 1 hour at room temperature with a suitable Alexa Fluor-conjugated secondary antibody (Molecular Probes, USA). The sections were then washed three times with PBS and the cell nuclei were counterstained with Hoechst 33342 (Sigma, USA). Images were taken using a confocal microscope (LSM 980, Zeiss) and analyzed using ImageJ software.

[0375] Western blot analysis

[0376] Cells or apoVs were collected and lysed on ice in a RIPA (CW2333S, CWBIO). Total protein concentration was measured using a BCA protein assay kit (23225, Invitrogen). Western blot analysis was performed using the following protocol: equal volumes of protein sample were loaded onto a NuPAGE Bis-Tris gel (NP0321BOX, Invitrogen) and transferred to a polyvinylidene fluoride membrane (ISEQ00010, Millipore). The membrane was sealed with 5% skim milk powder at room temperature for 1 hour, and then reacted with CD44 (ab189524, abcam), CD63 (sc-5275, Santa Cruz), CD9 (sc-13118, Santa Cruz), β-actin (A5441, sigma), caspase-3 (9662S, CST), calreticulin (12238S, CST), and calnexin (sc-23954, Santa Cruz) at 4°C. The membrane was incubated with primary antibodies containing Cruz, LDHA (ab101562, abcam), mTOR (2983S, CST), p-mTOR (2971S, CST), AMPK (2562S, CST), p-AMPK (2535S, CST), HK1 (A0533, Abcolonal), PFKL (A23687, Abcolock), PKM2 (4053S, CST), NAMPT (A22044, Abcock), and NRK1 (Santa-398852, Santa-398852). After washing with Tris-buffered saline (TBS) containing 0.1% Tween-20, the membrane was incubated with species-associated peroxidase-conjugated secondary antibodies at room temperature for 1 hour. Protein bands were observed using the SuperSignal West Pico PLUS chemiluminescent substrate kit (34580, Thermo Scientific) and the SuperSignal West Femto Maximum Sensitivity substrate kit (34095, Invitrogen), and analyzed using ChemiDoc. TM MP Imaging System (BIO-RAD, USA) Inspection.

[0377] Statistical data

[0378] For Kaplan-Meier curves, p-values ​​and hazard ratios (HRs) with 95% confidence intervals (CI) were generated using the log-rank test and univariate Cox proportional hazards regression. For normally distributed data, comparisons between two groups were analyzed using independent unpaired two-tailed Student's t-tests, and comparisons between more than two groups were analyzed using one-way ANOVA with Bonferroni adjustment. The Mann-Whitney test was used to compare other data. A p-value < 0.05 was considered statistically significant. All other statistical analyses were performed using GraphPad Prism 9 software.

[0379] Example 1: Apoptotic hepatocellular carcinoma (HCC) cell-derived apoVs produce LDHA to exacerbate M2. high and Treg high Immunosuppressive phenotype

[0380] This embodiment aims to explore the potential mechanism by which glycolysis in tumors significantly affects immunosuppressive tumor microenvironments (TME).

[0381] 1. Apoptosis in high-glycemic glycolysis liver cancer cells is related to the tumor immunosuppressive microenvironment in liver cancer patients.

[0382] Based on the analysis of glycolysis gene expression levels in the Cancer Genome Atlas (TCGA) database of 371 HCC cases (Figure 1A), the group with higher glycolysis and shorter overall survival was defined as the high glycolysis group, and the group with lower glycolysis and longest overall survival was defined as the low glycolysis group (Figures 1A and 1B).

[0383] Based on CIBERSORT scores (Jung, J., et al. (2022)) and TIDE scores (Jiang, P., et al. (2018)), it is inferred that patients with hyperglycemic glycolysis exhibit increased infiltration of M0, M2 macrophages and Treg cells, decreased infiltration of M1 macrophages, and CD8+. + T cell levels were similar, but ICB responses were low (Figures 2A, 1C, and 1D).

[0384] GSEA analysis of RNAseq data revealed a significant enrichment of apoptosis-related genes in tumor tissues of patients with high glycolysis (Figure 1E). Similarly, when patients were grouped based on the infiltration levels of M2 or Treg cells, M2 was found to be significantly enriched. high Treg high (Refers to a simultaneous high level of infiltration by both M2 and Treg), M2 high and Treg high The characteristics were also associated with the enrichment of apoptosis and glycolysis-related gene sets in tumor tissues (Figures 2B, 1F, and 1G). These results suggest that apoptosis in highly glycolytic tumor cells may be related to the immunosuppressive microenvironment that regulates HCC.

[0385] 2. ApoVs in liver cancer cells are associated with metabolic imbalance of immune cells and immunosuppression.

[0386] With high sugar glycolysis, M2 high Treg high In patients with high expression of apoptosis-related signaling pathways, LDHA expression was significantly higher (Figure 1H).

[0387] This embodiment further investigates whether apoptosis in highly glycolytic tumor cells enhances LDHA expression in immune cells to contribute to immunosuppressive tumor microenvironment (TME). This embodiment studies the relationship between tumor cell apoptosis and LDHA expression in the TCGA database, clinical HCC samples from this disclosure, and a mouse model of HCC receiving anti-PD-1 therapy. Results show that TCGA HCC patients with high apoptosis exhibit higher LDHA expression (Figure 2C).

[0388] This embodiment also performed immunofluorescence analysis, demonstrating that the increase in the number of apoptotic cells was associated with LDHA at F4 / 80. + Macrophages and CD4 + Increased expression in T cells and increased staining of M2-labeled CD206 and Treg-labeled Foxp3 in tumor tissues from HCC patients treated with PD-1 antibodies were positively correlated (Figures 2D and 1I).

[0389] Furthermore, although anti-PD-1 treatment reduced tumor volume in HCC mice (Figure 1J), PD-1 antibody treatment induced a large number of tumor cell apoptosis, accompanied by F4 / 80... + Macrophages and CD4 + High expression of LDHA in T cells and widespread transformational growth factor β (TGF-β) in HCC mouse tumors. + F4 / 80 + M2 macrophages and Foxp3 + Treg cell infiltration (Fig. 2E and 1K).

[0390] These results indicate a positive correlation between tumor cell apoptosis and immunosuppressive TME, which can be regulated by apoptosis-associated LDHA production. Since apoVs produced by apoptotic tumor cells can promote tumor malignancy (Pavlyukov, MS, et al. (2018)), this embodiment hypothesizes that tumor apoVs may be involved in LDH-mediated metabolic regulation of immune cells, thereby embodying an immunosuppressive phenotype in immune cells.

[0391] 3. Increased levels of lactate dehydrogenase in tumor tissue and circulating apoptotic vesicles.

[0392] This example compares changes in apoVs derived from tumor tissue in hepatocellular carcinoma (HCC) mice and finds that Annexin V in HCC mice treated with PD-1 monoclonal antibodies is significantly reduced. + LDHA + The number of double-positive apoVs was significantly higher in mice than in untreated HCC mice. Furthermore, circulating apoVs from HCC patient plasma also showed increased LDHA expression (Figure 3A).

[0393] 4. ApoV liver cancer cells exacerbate immunosuppression by restricting glycolytic metabolism in immune cells through lactate dehydrogenase.

[0394] To confirm this phenomenon, apoptosis was induced in mouse and human HCC cell lines using STS, and apoVs were isolated (Fig. 3B and 3C). Consistent with in vivo results, LDHA expression in apoVs derived from mouse and human HCC cells was significantly higher than that in apoVs derived from mouse hepatocytes or human endothelial cells (Fig. 2J and 3D).

[0395] Next, this embodiment uses apoVs derived from the mouse HCC cell line Hepa1-6 to investigate the function of tumor apoVs. Super-resolution structural microscopy (SIM), nanoflow cytometry, and Western blot analysis showed that mouse Hepa1-6-apoVs have a spherical structure and contain phosphatidylserine (PtdSer, derived from Annexin V). + (Indicated by) positive expression of apoVs marker cleaved caspase-3, Calreticulin and EVs marker CD9 (Zhang, X. et al. (2022) (Figure 3E-3G).

[0396] The steps for detecting LDHA expression of circulating apoVs in the plasma of the above HCC patients are as follows:

[0397] Blood samples were collected from HCC patients (n=5) and age-matched control subjects (n=5) in BD Vacutainer. TM The blood was placed in EDTA tubes and processed within 2 hours of blood collection. Plasma was prepared from the blood by centrifugation at 800g for 10 minutes at 4°C, followed by centrifugation at 2000g for 10 minutes at 4°C.

[0398] Next, the plasma was centrifuged at 16000g for 30 minutes at 4°C to separate the circulating apoVs, and then washed once with 0.1μm filtered PBS for the detection of LDHA in the circulating apoVs.

[0399] To investigate whether Hepa1-6-apoVs affect the metabolism of immune cells and enhance the immunosuppressive environment, this example uses macrophages and CD4 cells cultured in Hepa1-6 cell supernatant. + Hepa1-6-apoVs were added to T cells (Figure 3H). The results showed that macrophages and CD4 cells... + T cells take up more L-lactate and consume less glucose under low glucose and high L-lactate (LGHL) conditions, and Hepa1-6-apoVs treatment further confers these trends (Fig. 2K-2N), indicating that Hepa1-6-apoVs treatment increases lactate oxidation and inhibits glycolysis in immune cells. Furthermore, macrophages and CD4+ cells treated with tumor cell culture supernatant showed increased lactate oxidation and inhibited glycolysis. + T cells followed by NAD + Levels and NAD + The decrease in the NADH ratio and Hepa1-6-apoVs treatment enhanced tumor cell supernatant-mediated NAD+ resorption. + Reduction to NADH (Fig. 2O, 2P, and 3I-3L). These results indicate that HCC-derived apoVs enhance tumor metabolite-mediated glycolytic damage to immune cells, giving them a metabolic advantage in differentiating to a suppressive phenotype. Therefore, flow cytometry analysis revealed that Hepa1-6-apoVs further reduced macrophage and CD4+ cell activity. + CD86 in T cells + The proportion of inflammatory M1 macrophages increased, as did the immunosuppressive CD206. + The ratio of M2 macrophages to Treg cells (Figure 2Q and 2R).

[0400] This example demonstrates the role of LDHA in tumor apoVs. Treatment with Hepa1-6-apoVs (i.e., H-apoVs) was combined with the LDH inhibitor (LDHi) GSK 2837808a (Billiard, J., et al. (2013); Xie, H., et al. (2014)). The results showed that LDHi inhibited the pro-differentiation effect of Hepa1-6-apoVs on immunosuppressive M2 and Treg cells (Figures 3M and 3N). These data together suggest that Hepa1-6-apoVs produce more LDHA, which may contribute to impairing glycolytic metabolism in immune cells, thereby promoting M2 differentiation. high and Treg high Immunosuppressive phenotype.

[0401] Example 2: MSC-apoVs promote macrophages and CD4 + T-cell glycolysis to eliminate the immunosuppressive phenotype conferred by glycolytic tumor metabolites.

[0402] This embodiment explores whether MSC-apoVs can regulate metabolic imbalances in immune cells to reshape the immunosuppressive phenotype conferred by glycolytic tumor metabolites.

[0403] 1. Isolation and identification of MSC-apoVs

[0404] In this embodiment, MSC-apoVs were prepared and characterized. Specifically, MSC-apoVs were isolated after MSC apoptosis was induced by STS (Figures 3C and 4A-4D) (Liu, H. et al. (2020)). Nanoparticle tracking analysis (NTA), SIM, NanoFCM, and Western blot analysis showed that MSC-apoVs were spherical with an average size of 221.9 nm, positive for PtdSer staining, and positive expression of MSC marker CD44, apoV markers cleaved caspase-3, calcified and calreticulin, as well as EV markers CD63 and CD9 (Zhang, X. et al. (2022)) (Figures 4E-4I). These data indicate that the isolated MSC-apoVs were of high purity and met the criteria for extracellular vesicles.

[0405] 2. MSC-apoVs in vitro immune cell uptake

[0406] Furthermore, this embodiment explored the proteins enriched in MSC-apoVs compared to MSC-exo through KEGG pathway enrichment analysis. The results showed that the proteins enriched in MSC-apoVs were highly correlated with the regulation of multiple metabolic pathways, including glycolysis and oxidative phosphorylation (OXPHOS) (Figure 5A), indicating that MSC-apoVs may have the potential to regulate metabolic homeostasis.

[0407] This study investigated how MSC-apoVs regulate the metabolic homeostasis of immune cells and remodel the immunosuppressive tumor metabolites (TME) induced by glycolysis of tumor metabolites. Specifically, MSC-apoVs were added to macrophages and CD4 cells treated with conditioned medium. + In T cells. First, confocal microscopy and flow cytometry analysis showed that PKH26-labeled MSC-apoVs could be detected by macrophages and CD4+ cells. + Time-dependent uptake in T cells (Figs. 5B and 5C).

[0408] 3. MSC-apoVs balance the glycolytic metabolism of immune cells

[0409] Further analysis demonstrated that, unlike Hepa1-6-apoVs, MSC-apoVs (i.e., M-apoVs) enhanced glucose consumption under adequate glucose conditions. 13 C6]D-glucose's ability to produce L-lactic acid decreased L-lactic acid uptake under LGHL conditions (Figs. 5D-5F). Furthermore, MSC-apoVs increased macrophage and CD4+ uptake under tumor cell supernatant treatment. + NAD in T cells + Levels and NAD + The NADH ratio was increased, and compared with Hepa1-6-apoVs treatment, it promoted NAD+. + The conversion to NADH (Figure 4J-4O).

[0410] Phosphorylation of AMP-activated protein kinase (AMPK), which subsequently inhibits the mammalian target of rapamycin (mTOR) pathway, reduces glycolysis and promotes oxidative phosphorylation, thereby inhibiting the metabolic reprogramming of immune cells into innate immunity and promoting immunosuppressive phenopolarization (Kelly, B. et al. (2015); Sag, D. et al. (2008); Chi, H. et al. (2012)). To further verify that MSC-apoVs can promote macrophage and CD4+... + In this study, T cell glycolysis was investigated using Western blot analysis to examine the AMPK / mTOR pathway. The results showed that in macrophages and CD4+ T cells treated with tumor cell supernatant, MSC-apoVs significantly reduced AMPK phosphorylation and increased mTOR phosphorylation (Figure 5G), while the opposite trend was observed in cells treated with Hepa1-6-apoVs. These results indicate that MSC-apoVs can inhibit lactate oxidation and rescue damaged glycolytic metabolism in immune cells.

[0411] 4. MSC-apoVs reverse immunosuppressive phenotype

[0412] Next, this example demonstrates that, compared to Hepa1-6-apovs, treatment of tumor cell supernatant with MSC-apoVs induces macrophages and CD4+. +Following T cell initiation, M1 polarization increased, M2 polarization decreased, and Treg cell differentiation declined (Figs. 5H and 5I). These results indicate that MSC-apoVs can eliminate the immunosuppressive phenotype induced by tumor metabolites. Since tumor Treg cells mainly migrate from peripheral lymphoid tissues via macrophage chemotaxis (Gobert, M., et al. (2009)), this study performed a Transwell assay to assess whether MSC-apoVs could affect Treg cell migration to macrophages. The results showed that tumor cell supernatant increased macrophage-chemotactically attracted Treg cell migration, while MSC-apoVs significantly inhibited this process (Fig. 4P). Furthermore, RT-PCR analysis revealed that tumor cell supernatant increased the expression of the chemokine CC motif ligand 22 (CCL22) in macrophages. This chemokine plays a crucial role in the recruitment of Treg cells (Gobert, M. et al. (2009); Fisher, JD et al. (2020)), but this promoting effect could be inhibited by MSC-apoVs (Figure 4Q). These data suggest that MSC-apoVs can rebalance glycolysis and lactate oxidation, reversing the immunosuppressive phenotype.

[0413] Example 3: MSC-apoVs inhibit M2 high and Treg high Immunosuppressive TME to induce cytotoxic CD8 + T cell infiltration and tumor suppression in HCC mice

[0414] 1. Distribution of immune cells in vivo after MSC-apoVs injection

[0415] In this embodiment, the effect of MSC-apoVs on immunosuppressive TME was evaluated by injecting MSC-apoVs into HCC mice via the tail vein (Figure 6A).

[0416] The biodistribution of EVs is crucial for their therapeutic efficacy (Nishida-Aoki et al. (2020)). In this example, PKH26-labeled MSC-apoVs were first injected into HCC mice. It was found that 3 hours post-injection, large amounts of MSC-apoVs accumulated in the tumor, lymph nodes, and spleen, and remained at high levels for 24 hours post-injection (Figures 7A-7C). Further confocal microscopy analysis showed that PKH26-labeled MSC-apoVs were present in the F4 / 80 region of the tumor. + CD4 in macrophages, lymph nodes, and spleen + T cells (Figure 6B) indicate that intravenously injected MSC-apoVs have the potential to modulate immune cells in tumors and peripheral lymphoid organs.

[0417] 2. MSC-apoVs balance metabolism in HCC mice, reversing immunosuppressive phenotype and reducing tumor volume.

[0418] In this embodiment, immune cells infiltrating HCC mouse tumors were isolated and analyzed by flow cytometry and immunofluorescence (IF) staining. The results showed that infusion of MSC-apoVs significantly increased the number of M1 macrophages (CD45) infiltrating the tumor. + Lin - CD11b + F4 / 80 + CD86 + And inhibit M2 (CD45) + Lin - CD11b + F4 / 80 + CD206 + The tumor cells differentiated into M2 cells (Figs. 6C, 6D, and 7D). IF staining further confirmed the inhibitory effect of MSC-apoVs on M2 and the promoting effect on M1 in tumors (Figs. 6E-6F). MSC-apoVs treatment significantly reduced the number of Treg cells (CD45+) in tumor tissue. + CD4 + CD25 + FoxP3 + The infiltration of MSC-apoVs and the proportion of Treg cells in peripheral lymphoid organs (including spleen, forelimb, and portal vein lymph nodes) were observed (Fig. 6G, 7E-7G). IF staining further confirmed that MSC-apoVs infusion could inhibit the infiltration of Treg cells in tumor tissue (Fig. 6H).

[0419] Compared with the untreated HCC group, MSC-apoVs also increased IFN-γ + Effect CD8 + T cell infiltration, reduced LAG3 + PD-1 + Exhaustion CD8 + The proportion of T cells, thereby increasing the effector CD8 + With depletion CD8 + The ratio of T cells (Figs. 6I-6K and 7H). These findings suggest that MSC-apoVs can suppress the infiltration of M2 and Treg cells in tumors and reduce Treg cells in peripheral lymphoid organs before entering the TME, thereby enabling cytotoxic CD8. + Increased T-cell infiltration. In this example, by examining tumors in HCC mice, we found that MSC-apoVs infusion inhibited hepatocellular carcinoma growth, as indicated by reduced tumor size and tumor damage (Figs. 6L, 6M, and 7I).

[0420] Furthermore, this embodiment also investigated whether MSC-apoVs could regulate metabolic homeostasis in HCC mouse tumors. Consistent with in vitro experiments, MSC-apoVs treatment upregulated NAD50 in immune cells within tumor tissue. + The LDH / NADH ratio (Figures 7J-7L) was also significantly reduced. Furthermore, MSC-apoVs treatment significantly inhibited LDH activity in tumor and lymph node immune cells (Figures 7M and 7N), indicating that MSC-apoVs can inhibit lactate oxidation in HCC mouse immune cells.

[0421] Example 4: MSC-apoVs transfer multiple factors to eliminate LDHA-mediated glycolysis inhibition and promote NAD. + Metabolic initiation of immune cell glycolysis

[0422] 1. MSC-apoVs eliminate the inhibition of glycolysis in immune cells by lactate dehydrogenase via miR-34c-5p.

[0423] This study aimed to investigate the molecular mechanism by which MSC-apoVs regulate metabolic imbalance in immune cells. Western blot analysis was used to detect LDHA, which inhibits glycolysis, and three restriction enzymes involved in glycolysis: hexokinase-1 (HK1), liver-type 6-phosphofructokinase (PFKL), and pyruvate kinase isozymes M2 (PKM2) (Leung, SWS et al. (2022); Angelin, A. et al. (2017)). MSC-apoVs treatment downregulated the levels of macrophages and CD4+ in tumor cell supernatant-treated cells. + The expression of LDHA in T cells upregulated the expression of HK1 and PFKL (Figures 8A and 8B), demonstrating the potential of MSC-apoVs to reverse LDHA-mediated glycolysis inhibition.

[0424] Since apoVs can deliver microRNAs (miRNAs) to host cells, thereby silencing genes at the posttranscriptional level (Zernecke, A., et al. (2009)), this embodiment aims to explore the potential role of miRNAs in the inhibitory effect of apoVs on LDHA. Using the online software DIANA and TargetScan, five miRNAs that may target LDHA gene expression were predicted (Figure 9A). RT-PCR showed that MSC-apoVs treatment increased miR-34c-5p expression in macrophages (Figure 8C). To verify the function of miR-34c-5p, miR-34c-5p inhibitors were transfected into MSCs, and miR-34c-5p-deficient apoVs (anti-miR apoVs) were isolated. Western blot analysis showed that anti-miR apoVs significantly increased expression in macrophages and CD4+ cells treated with tumor cell supernatant. + The ability of T cells to downregulate LDHA expression is impaired (Figs. 8D and 8E).

[0425] Functionally, anti-miR apoVs lost their ability to reverse the immunosuppressive phenotype of immune cells. Compared with the control group MSC-apoVs, they showed reduced activity against macrophages and CD4+ cells in tumor cell supernatant. + For T cells, the ability to enhance M1 and reduce M2 macrophage polarization was weakened, and the ability to inhibit Treg cell differentiation was reduced (Figures 8F-8J). These data suggest that MSC-apoVs exert their inhibitory effect on the LDHA-mediated immunosuppressive phenotype by transporting miR-34c-5p.

[0426] LDHA mediates the dual metabolism of lactate, namely lactate formation and lactate reabsorption and reuse. Inhibiting LDHA can reduce the production of lactate oxidation-dependent NADH and pyruvate, limit the OXPHOS process, and thus reduce NAD. + The results of this embodiment indicate that MSC-apoVs treatment not only reduces NADH levels but also increases NAD+ levels. + The level of NAD+ in macrophages treated with tumor cell supernatant is thus reduced. + The NADH / NADH ratio was significantly increased (Figure 8K-8M). Furthermore, the absence of miR-34c-5p blocked the inhibitory effect of apoVs on NADH levels, but failed to attenuate their effect on NAD. + The effects of miR-34c-5p levels (Figures 8K-8M). These data suggest that although miR-34c-5p inhibits LDHA function, other factors may be involved in MSC-apoVs-mediated NAD. + Synthesis (Figure 8N).

[0427] 2. MSC-apoVs promote NAD through NAMPT + De novo synthesis-initiated immune cell glycolysis

[0428] NAD + The most important biosynthetic pathway is the rescue pathway, in which nicotinamide riboside kinase (NMRK) and nicotinamide phosphoribosyltransferase (NAMPT) are NAD+ kinases. + Rate-limiting enzymes in the rescue pathway (Chowdhry, S., et al. (2019); Fletcher, RS, et al. (2018)). Proteomic analysis of MSC-apoVs showed that NMRK1 and NAMPT were enriched in MSC-apoVs (Figure 10A). Western blot analysis was further performed in this embodiment, and the results showed that MSC-apoVs were enriched in macrophages and CD4+ cells cultured from tumor cell supernatant. + NAMPT expression was upregulated in all T cells, but NMRK1 expression was upregulated only in macrophages (Figs. 10B and 10C). Therefore, in the following study, this example also explored the function of NAMPT in MSC-apoVs. NAMPT expression in MSCs was knocked down using siRNA (Fig. 9B), and NAMPT-knocked MSC-apoVs (NAMPT KD-apoVs) were isolated. Western blot analysis showed that macrophages treated with tumor cell supernatant and CD4+ were upregulated. + In T cells, the ability of NAMPTKD-apoVs to promote NAMPT expression is impaired (Fig. 10D and 10E).

[0429] Functionally, compared with control MSC-apoVs, macrophages and CD4+ cells treated with tumor cell supernatant showed improved activity. + For T cells, the ability to enhance M1 and reduce M2 macrophage polarization was weakened, and the ability to inhibit Treg cell differentiation was reduced (Figures 10F-10J), failing to reverse the immunosuppressive phenotype of immune cells. Furthermore, NAMPT knockdown blocked apoVs' inhibition of NAD50. + The apoVs enhance the level of NAD, but do not affect the level of NADH, thus increasing the level of NAD. + The effect of the NADH / g / dT ratio is weakened (Figure 10K-10M). These findings suggest that MSC-apoVs may reverse LDHA-mediated glycolysis inhibition by transporting miR-34c-5p and promote NAD+ by transporting NAMPT. +Anabolic glycolysis of immune cells (Fig. 8N and Fig. 10N).

[0430] Because HCC cell-derived apoVs impair glycolysis in immune cells and promote an immunosuppressive phenotype (Figure 2K-2R), this study further investigated whether HCC cell-derived apoVs contain components that have the opposite effect to MSC-apoVs. RT-PCR and Western blot analyses showed that, compared with MSC-apoVs, Hepa1-6-apoVs expressed significantly lower levels of miR-34c-5p, higher levels of LDHA, and similar levels of NAMPT (Figures 9C and 9D).

[0431] Furthermore, the TCGA dataset showed that HCC patients with low miR-34c-5p hyperglycemia had lower overall survival compared to those with high miR-34c-5p hyperglycemia (Figure 9E). Additionally, Hepa1-6-apoVs failed to inhibit LDHA and increase NAMPT expression, and also failed to promote the expression of macrophages and CD4+ in tumor cell supernatant-treated cells. + Expression of the rate-limiting glycolysis enzymes HK1 and PFKL in T cells (Figures 9F and 9G).

[0432] Example 5: MSC-apoVs eliminate immunosuppressive TME and enhance anti-tumor immunity to strengthen anti-PD-1 treatment in HCC mice.

[0433] This embodiment then explores the therapeutic potential of combined MSC-apoVs and anti-PD-1 therapy in an orthotopic HCC mouse model (Figure 11A).

[0434] 1. Combination therapy of MSC-apoVs and PD-1 monoclonal antibodies reverses the immunosuppressive phenotype and enhances the effector CD8. + T cell ratio

[0435] In constructing orthotopic HCC mice and treating them with MSC-apoVs and PD-1 monoclonal antibodies, alone or in combination, the results showed that although anti-PD-1 treatment reduced LAG3 in HCC mice... + PD-1 + Exhaustion CD8 + The percentage of T cells increased IFN-γ + Effect CD8 + T cell infiltration and effector CD8 + With depleted CD8 + The ratio of Treg cells was high (Figs. 11B-11D and 12A), but at the same time, the infiltration of Treg cells in the TME and the percentage of Treg cells in the lymph nodes and spleen remained at a high level (Figs. 11E, 11F and 12B-12E), which led to a high ratio of Treg cells to effector CD8 cells.+ A significantly increased T-cell ratio (Figure 11G) may promote immunosuppressive TME during anti-PD-1 therapy.

[0436] Furthermore, anti-PD-1 treatment slightly increased M1 macrophage infiltration in the tumor and mildly inhibited M2 macrophage infiltration, resulting in a higher M2 / M1 ratio than the MSC-apoVs treatment group. This may help recruit more Treg cells (Figures 11H-11L and 12F-12H). Compared with the untreated group and HCC mice treated with MSC-apoVs or anti-PD-1 alone, the combination therapy of MSC-apoVs and anti-PD-1 further enhanced the effector CD8+. + T / Exhaustion CD8 + The combination therapy reduced the proportion of T cells and inhibited the infiltration of Treg cells and M2 macrophages in the tumor (Figs. 11B-11L), while also reducing the proportion of Treg cells in the lymph nodes and spleen (Figs. 11D and 12E). Therefore, the combination therapy resulted in a Treg / CD8 ratio in the TME. + The reduced T cell and M2 / M1 cell ratio (Figures 11G and 11L) eliminated immunosuppression in the TME and enhanced anti-tumor immunity.

[0437] 2. Combination therapy with MSC-apoVs and PD-1 monoclonal antibodies further reduced tumor volume in orthotopic HCC mice.

[0438] More importantly, compared with monotherapy of MSC-apoVs or anti-PD-1, combination therapy significantly enhanced the anti-tumor efficacy, as the tumor volume and lesion were smallest in all four groups of orthotopic HCC mice after combination therapy (Figures 11M, 11N, and 12I). Compared with monotherapy, combination therapy increased the level of tumor cell apoptosis and reduced the number of Ki67-positive proliferating cells (Figures 12J and 12K).

[0439] 3. Combination therapy of MSC-apoVs and PD-1 monoclonal antibodies balances immune cell metabolism.

[0440] This embodiment further investigates whether combination therapy can regulate metabolic homeostasis in HCC mice. Anti-PD-1 monotherapy significantly upregulated NADH levels in tumor immune cells of orthotopic HCC mice (Figures 13A-13C). NAD+ levels in tumors of orthotopic HCC mice after combination therapy with anti-PD-1 and MSC-apoVs were also observed. + Levels and NAD +The ratios of MSC-apoVs to NADH were all increased (Figs. 13A-13C), and these changes may promote glycolysis in TME immune cells. Furthermore, compared with anti-PD-1 monotherapy, the combination therapy significantly inhibited LDH activity in immune cells in tumors and lymph nodes (Figs. 13D and 13E), indicating that lactate oxidation in immune cells was suppressed. RT-PCR and immunofluorescence staining further confirmed that, compared with the control group and anti-PD-1 treated mice, MSC-apoVs infusion and combination therapy increased miR-34c-5p expression in orthotopic HCC mouse tumor tissues and upregulated F4 / 80 in tumor tissues. + Macrophages and CD4 + NAMPT expression in T cells (Figures 13F-13H). These results indicate that MSC-apoVs enhance anti-tumor immunity and promote anti-PD-1 therapy by regulating the metabolic homeostasis of immune cells, eliminating immunosuppressive TMEs. Furthermore, combination therapy provides an effective strategy for the comprehensive treatment of HCC.

[0441] Example 6: Diagnostic efficacy test of tumor markers for liver cancer

[0442] 1. Isolation and detection of circulating apoVs in human blood samples

[0443] Blood samples were collected from patients with hepatocellular carcinoma (HCC) (n=30) and age-matched healthy controls (n=10), patients with hepatitis B (n=10), and patients with cirrhosis (n=10) at BD Vacutainer. TM The samples were placed in EDTA anticoagulant tubes and processed within 2 hours after intravenous puncture. Whole blood was centrifuged at 800g, 4°C for 10 minutes to obtain plasma, which was then centrifuged again at 2000g, 4°C for 10 minutes. The supernatant was collected and centrifuged at 16000g for 30 minutes at 4°C to separate circulating apoptotic vesicles (apoVs). The precipitate was washed once with 0.1μm filtered PBS (16000g, 30 minutes). Subject information is shown in Table 3.

[0444] Recombinant anti-lactate dehydrogenase LDHA antibody (ab101562, abcam) was diluted 1:100 with 0.1 μm filtered PBS and incubated with the isolated circulating apoVs at 4°C for 1 hour. After incubation, the mixture was centrifuged at 16000g for 30 minutes at 4°C, and the supernatant was discarded to remove unbound primary antibody. Then, the corresponding Alexa Fluor-labeled secondary antibody (Molecular Probes, USA) was added, and the mixture was incubated at room temperature in the dark for 1 hour. It was then centrifuged again at 16000g for 30 minutes at 4°C, and the unbound secondary antibody was washed away. Next, FITC Annexin V (556419, BD Biosciences) was dissolved in 1×Annexin V binding buffer (556454, BD Pharmingen), and the treated apoVs were stained at 4°C in the dark for 15 minutes. After staining, the apoVs were ready for detection using a nanoflow cytometer (U30, China). The separation and detection process of circulating apoVs is shown in Figure 14.

[0445] Table 3 Subject Information

[0446] 2. Data Analysis Methods: Statistical software was used to analyze the data.

[0447] To investigate the diagnostic efficacy of different tumor markers for hepatocellular carcinoma (HCC), receiver operating characteristic (ROC) curves were plotted to evaluate their predictive ability. The level corresponding to the highest Youden index (Youden index = sensitivity + specificity - 1) was selected as the cutoff value. Based on the determined cutoff value, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of each detection protocol were calculated.

[0448] The sensitivity calculation method is: the percentage of HCC patients whose test results are higher than the cutoff value out of all HCC patients.

[0449] The specificity calculation method is: the percentage of non-HCC patients whose test results are below the cutoff value out of the total number of non-HCC patients.

[0450] The diagnostic efficacy test results of individual indicators, including AFP and LDHA, were used. + AV + The proportion of apoVs is a tumor marker, which was measured in clinical samples. The corresponding maximum value and optimal cutoff value of the Youden index are shown in Table 4.

[0451] Table 4 AFP and LDHA+ AV + The maximum value and cutoff value of the Youden index corresponding to apoVs(%)

[0452] A detailed evaluation of diagnostic efficacy was conducted based on the optimal probability thresholds determined in Table 4, and the results for AFP and LDHA were calculated. + AV + The diagnostic efficacy of apoVs ratio alone for liver cancer is evaluated, as shown in Table 5.

[0453] Table 5. Evaluation results of the diagnostic efficacy of each indicator for liver cancer.

[0454] This study included 60 participants, comprising 10 healthy controls, 10 patients with hepatitis B, 10 patients with cirrhosis, and 30 patients with liver cancer. AFP and LDHA levels were compared among the participants. + AV + The proportions of apoVs were compared and presented in a bar chart (Figure 15A). Further univariate statistical analysis was used to analyze the above indicators, and ROC curves were plotted (Figure 15B). The results show that LDHA... + AV + The proportion of apoVs is better than that of traditional AFP tests in terms of diagnostic specificity and sensitivity.

[0455] LDHA + AV + Correlation analysis of the proportion of apoVs and tumor diameter (Figures 16A and 16B) confirmed LDHA. + AV + The proportion of apoVs can indicate the severity of the disease and is superior to AFP.

[0456] From the above experimental results, we can conclude that:

[0457] LDHA + AV + The proportion of apoVs, as a novel diagnostic marker, has a very high correlation with liver cancer. At the optimal cutoff value of 50.2000%, its sensitivity is as high as 93.33%, and its specificity is as high as 96.67%. Its Youden index (0.9000) and area under the curve (AUC: 0.9633) are significantly better than the traditional clinical indicator AFP.

[0458] The traditional biomarker AFP, while exhibiting good specificity (90.00%) at a cutoff value of 7.3900 ng / mL, has a sensitivity of only 76.67%, posing a high risk of missed diagnoses.

[0459] The LDHA provided by this invention + AV+ The apoVs ratio assay kit boasts extremely high accuracy, effectively preventing missed or misdiagnosed cases. This is clinically invaluable, enabling early detection of liver cancer, buying patients valuable time to begin treatment sooner, and improving survival rates—a matter of significant clinical importance.

[0460] The above embodiments are merely preferred embodiments of this application and should not be construed as limiting the scope of protection of this application. Any non-substantial changes and substitutions made by those skilled in the art based on this application shall fall within the scope of protection claimed by this application.

[0461] References

[0462] 1.Reinfeld,BI,et al.(2022).The therapeutic implications of immunosuppressive tumor aerobic glycolysis.Cell Mol Immunol 19,46-58.10.1038 / s41423-021-00727-3.

[0463] 2. Callahan, MK, et al. (2016). Targeting T Cell Co-receptors for Cancer Therapy. Immunity 44, 1069-1078.10.1016 / j.immuni.2016.04.023.

[0464] 3. Zhu, AX, et al. (2022). Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med 28, 1599-1611.10.1038 / s41591-022-01868-2.

[0465] 4.Finn,RS,et al.(2020).Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.N Engl J Med 382,1894-1905.10.1056 / NEJMoa1915745.

[0466] 5.Sharma,P.,et al.(2017).Primary,Adaptive,and Acquired Resistance to Cancer Immunotherapy.Cell 168,707-723.10.1016 / j.cell.2017.01.017.

[0467] 6.Arlauckas,S.P.,et al.(2017).In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.Sci Transl Med 9.10.1126 / scitranslmed.aal3604.

[0468] 7.Dong,L.,et al.(2021).The loss of RNA N(6)-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8(+)T cell dysfunction and tumor growth.Cancer Cell 39,945-957 e910.10.1016 / j.ccell.2021.04.016.

[0469] 8.Togashi,Y.,et al.(2019).Regulatory T cells in cancer immunosuppression-implications for anticancer therapy.Nat Rev Clin Oncol 16,356-371.10.1038 / s41571-019-0175-7.

[0470] 9.Bouillet,P.,et al.(1999).Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses,leukocyte homeostasis,and to preclude autoimmunity.Science 286,1735-1738.10.1126 / science.286.5445.1735.

[0471] 10.Mattson,M.P.(2000).Apoptosis in neurodegenerative disorders.Nat Rev Mol Cell Biol 1,120-129.10.1038 / 35040009.

[0472] 11.Gougeon,M.L.(2003).Apoptosis as an HIV strategy to escape immune attack.Nat Rev Immunol 3,392-404.10.1038 / nri1087.

[0473] 12.Papadaki,H.A.,et al.(2003).Impaired granulocytopoiesis in patients with chronic idiopathic neutropenia is associated with increased apoptosis of bone marrow myeloid progenitor cells.Blood 101,2591-2600.10.1182 / blood-2002-09-2898.

[0474] 13.Wang,R.,Hao,et al.(2023).Apoptotic vesicles ameliorate lupus and arthritis via phosphatidylserine-mediated modulation of T cell receptor signaling.Bioact Mater 25,472-484.10.1016 / j.bioactmat.2022.07.026.

[0475] 14.Weavers,H.,et al.(2016).Corpse Engulfment Generates a Molecular Memory that Primes the Macrophage Inflammatory Response.Cell 165,1658-1671.10.1016 / j.cell.2016.04.049.

[0476] 15.Wiklander,O.P.B.,et al.(2019).Advances in therapeutic applications of extracellular vesicles.Sci Transl Med 11.10.1126 / scitranslmed.aav8521.

[0477] 16.Friedenstein,A.J.,et al(1974).Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues.Cloning in vitro and retransplantation in vivo.Transplantation 17,331-340.10.1097 / 00007890-197404000-00001.

[0478] 17.Liu,Y.,et al.(2011).Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha.Nat Med 17,1594-1601.10.1038 / nm.2542.

[0479] 18.Sun,L.,et al.(2009).Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans.Stem Cells 27,1421-1432.10.1002 / stem.68.

[0480] 19.Liu,D.,et al.(2018).Circulating apoptotic bodies maintain mesenchymal stem cell homeostasis and ameliorate osteopenia via transferring multiple cellular factors.Cell Res 28,918-933.10.1038 / s41422-018-0070-2.

[0481] 20.Ou,Q.,et al.(2022).Electrostatic Charge-Mediated Apoptotic Vesicle Biodistribution Attenuates Sepsis by Switching Neutrophil NETosis to Apoptosis.Small 18,e2200306.10.1002 / smll.202200306.

[0482] 21.Zheng,C.,et al.(2021).Apoptotic vesicles restore liver macrophage homeostasis to counteract type 2 diabetes.J Extracell Vesicles 10,e12109.10.1002 / jev2.12109.

[0483] 22.Wang,J.,et al.(2021).Apoptotic Extracellular Vesicles Ameliorate Multiple Myeloma by Restoring Fas-Mediated Apoptosis.ACS Nano 15,14360-14372.10.1021 / acsnano.1c03517.

[0484] 23.Pavlyukov,et al.(2018).Apoptotic Cell-Derived Extracellular Vesicles Promote Malignancy of Glioblastoma Via Intercellular Transfer of Splicing Factors.Cancer Cell 34,119-135 e110.10.1016 / j.ccell.2018.05.012.

[0485] 24.Wang,Y.,et al.(2014).Plasticity of mesenchymal stem cells in immunomodulation:pathological and therapeutic implications.Nat Immunol 15,1009-1016.10.1038 / ni.3002.

[0486] 25.He,Y.,et al.(2022).Mesenchymal stem cells empower T cells in the lymph nodes via MCP-1 / PD-L1 axis.Cell Death Dis 13,365.10.1038 / s41419-022-04822-9.

[0487] 26.Baldominos,P.,et al.(2022).Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche.Cell 185,1694-1708 e1619.10.1016 / j.cell.2022.03.033.

[0488] 27.Bergsmedh,A.,et al.(2001).Horizontal transfer of oncogenes by uptake ofapoptotic bodies.Proc Natl Acad Sci U S A 98,6407-6411.10.1073 / pnas.101129998.

[0489] 28.Zernecke,A.,et al.(2009).Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection.Science signaling 2,ra81.10.1126 / scisignal.2000610.

[0490] 29.Warburg,O.(1956).On the origin of cancer cells.Science 123,309-314.10.1126 / science.123.3191.309.

[0491] 30.Leone,R.D.,et al.(2020).Metabolism of immune cells in cancer.Nat Rev Cancer 20,516-531.10.1038 / s41568-020-0273-y.

[0492] 31.Brand,A.,et al.(2016).LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.Cell Metab 24,657-671.10.1016 / j.cmet.2016.08.011.

[0493] 32.Colegio,et al.(2014).Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.Nature 513,559-563.10.1038 / nature13490.

[0494] 33.Watson,M.J.,et al.(2021).Metabolic support of tumour-infiltrating regulatory T cells by lactic acid.Nature 591,645-651.10.1038 / s41586-020-03045-2.

[0495] 34.Zhang,L.,et al.(2023).STING is a cell-intrinsic metabolic checkpoint restricting aerobic glycolysis by targeting HK2.Nat Cell Biol 25,1208-1222.10.1038 / s41556-023-01185-x.

[0496] 35.Guo,C.,et al.(2023).SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity.Nature 620,200-208.10.1038 / s41586-023-06299-8.

[0497] 36.Ma,L.,et al.(2023).Apoptotic extracellular vesicles are metabolized regulators nurturing the skin and hair.Bioact Mater 19,626-641.10.1016 / j.bioactmat.2022.04.022.

[0498] 37.Zhu,Y.,et al.(2023).Apoptotic Vesicles Regulate Bone Metabolism via the miR1324 / SNX14 / SMAD1 / 5 Signaling Axis.Small 19,e2205813.10.1002 / smll.202205813.

[0499] 38.Newman,et al.(2015).Robust enumeration of cell subsets from tissue expression profiles.Nat Methods 12,453-457.10.1038 / nmeth.3337.

[0500] 39.Chen,B.,et al.(2018).Profiling Tumor Infiltrating Immune Cells with CIBERSORT.Methods Mol Biol 1711,243-259.10.1007 / 978-1-4939-7493-1_12.

[0501] 40.Jiang,P.,et al.(2018).Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.Nat Med 24,1550-1558.10.1038 / s41591-018-0136-1.

[0502] 41.Gimble,J.M.,et al.(2007).Adipose-derived stem cells for regenerative medicine.Circ Res 100,1249-1260.10.1161 / 01.RES.0000265074.83288.09.

[0503] 42.Zhang,X.,et al.(2022).Proteomic analysis of MSC-derived apoptotic vesicles identifies Fas inheritance to ameliorate haemophilia a via activating platelet functions.J Extracell Vesicles 11,e12240.10.1002 / jev2.12240.43.Jung,J.,et al.(2022).Clinical Significance of Glycolytic Metabolic Activity in Hepatocellular Carcinoma.Cancers(Basel)15.10.3390 / cancers15010186.

[0504] 44.Billiard,J.,et al.(2013).Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells.Cancer Metab 1,19.10.1186 / 2049-3002-1-19.

[0505] 45.Xie,H.,et al.(2014).Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells.Cell Metab 19,795-809.10.1016 / j.cmet.2014.03.003.

[0506] 46.Liu,H.,et al.(2020).Donor MSCs release apoptotic bodies to improve myocardial infarction via autophagy regulation in recipient cells.Autophagy 16,2140-2155.10.1080 / 15548627.2020.1717128.

[0507] 47.Kelly,B.,et al.(2015).Metabolic reprogramming in macrophages and dendritic cells in innate immunity.Cell Res 25,771-784.10.1038 / cr.2015.68.

[0508] 48.Sag,D.,et al.(2008).Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype.J Immunol 181,8633-8641.10.4049 / jimmunol.181.12.8633.

[0509] 49.Chi,H.(2012).Regulation and function of mTOR signalling in T cell fate decisions.Nat Rev Immunol 12,325-338.10.1038 / nri3198.

[0510] 50.Gobert,M.,et al.(2009).Regulatory T cells recruited through CCL22 / CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.Cancer Res 69,2000-2009.10.1158 / 0008-5472.CAN-08-2360.

[0511] 51.Fisher,J.D.,et al.(2020).In situ recruitment of regulatory T cells promotes donor-specific tolerance in vascularized composite allotransplantation.Sci Adv 6,eaax8429.10.1126 / sciadv.aax8429.

[0512] 52.Nishida-Aoki,N.,et al.(2020).Altered biodistribution of deglycosylated extracellular vesicles through enhanced cellular uptake.J Extracell Vesicles 9,1713527.10.1080 / 20013078.2020.1713527.

[0513] 53.Leung,S.W.S.,et al.(2022).The glycolytic process in endothelial cells and its implications.Acta Pharmacol Sin 43,251-259.10.1038 / s41401-021-00647-y.

[0514] 54.Angelin,A.,et al.(2017).Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose,High-Lactate Environments.Cell Metab 25,1282-1293 e1287.10.1016 / j.cmet.2016.12.018.

[0515] 55.Chowdhry,S.,et al.(2019).NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling.Nature 569,570-575.10.1038 / s41586-019-1150-2.

[0516] 56. Fletcher, RS, et al. (2018). The emergence of the nicotinamide riboside kinases in the regulation of NAD+metabolism. J Mol Endocrinol 61, R107-R121.10.1530 / JME-18-0085.

[0517] The embodiments described in this disclosure are merely illustrative examples. The embodiments of this disclosure are not limited to the above. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of this disclosure shall be considered equivalent substitutions and shall be included within the protection scope of this disclosure.

Claims

1. Use of induced vesicles in the preparation of antitumor drugs for use in combination with immunotherapy agents.

2. Use of immunotherapeutic agents in the preparation of antitumor drugs for use in combination with induced vesicles.

3. The use as described in claim 1 or 2, wherein, The induced vesicles are vesicles that are generated when stem cells or somatic cells are in normal survival and apoptosis is induced by external factors. In particular, the induction methods include adding astrocytocin, ultraviolet irradiation, starvation, or thermal stress. In particular, the stem cells are selected from mesenchymal stem cells; In particular, the mesenchymal stem cells are derived from bone marrow, dental pulp, urine, oral cavity, fat, placenta, umbilical cord, periosteum, tendon, or peripheral blood. In particular, the diameter of the induced vesicles is approximately 0.03-10 μm; In particular, the diameter of the induced vesicles is approximately 0.03-6 μm; In particular, the diameter of the induced vesicles is approximately 0.03-4.5 μm; In particular, the diameter of the induced vesicles is approximately 0.03-1 μm; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 1–1500 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 10–800 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 100–800 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 200–700 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 300–600 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 400–600 nM; In particular, the time to induce apoptosis by adding astrosporin is approximately 2–24 hours; In particular, the time to induce apoptosis by adding astrosporin is approximately 2–15 hours; In particular, the time to induce apoptosis by adding astrosporin is approximately 2–10 hours; In particular, the induced vesicles showed higher expression of the biomarker Syntaxin 4 than MSCs or exosomes of the same origin; In particular, the markers also include one or more of Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5; In particular, the induced vesicles are highly expressed by the markers Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5; In particular, the expression levels of the markers Annexin V, Flotillin-1, Cadherin 11, and Integrin alpha 5 in the induced vesicles were higher than those in MSCs or exosomes of the same origin. In particular, the inducible vesicles are highly expressed by the markers cleaved caspase-3, Calnexin, Calreticulin, CD63, CD9, caspase-3, and CD44; In particular, the immunotherapy agent is an immunotherapy drug; In particular, the immunotherapeutic agent includes an anti-PD-1 antibody or an anti-PD-L1 antibody; In particular, the anti-PD-1 antibody is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, CT-011, AMP-224, MPDL3280A, MEDI4736 or MDX-1105; In particular, the anti-PD-L1 antibody is avirumab, durvalumab, or atezolizumab; In particular, the tumor is selected from solid tumors or hematologic malignancies; In particular, the solid tumor was selected from liver cancer.

4. Use of induced vesicles in the preparation of drugs to improve or treat poor prognoses of tumor immunotherapy; In particular, the induced vesicles are vesicles generated by inducing apoptosis in stem cells or somatic cells when they are in normal survival by adding external factors; In particular, the induction methods include adding astrocytocin, ultraviolet irradiation, starvation, or thermal stress. In particular, the stem cells are selected from mesenchymal stem cells; In particular, the mesenchymal stem cells are derived from bone marrow, dental pulp, urine, oral cavity, fat, placenta, umbilical cord, periosteum, tendon, or peripheral blood. In particular, the diameter of the induced vesicles is approximately 0.03-10 μm; In particular, the diameter of the induced vesicles is approximately 0.03-6 μm; In particular, the diameter of the induced vesicles is approximately 0.03-4.5 μm; In particular, the diameter of the induced vesicles is approximately 0.03-1 μm; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 1–1500 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 10–800 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 100–800 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 200–700 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 300–600 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 400–600 nM; In particular, the induced vesicles showed higher expression of the biomarker Syntaxin 4 than MSCs or exosomes of the same origin; In particular, the markers also include one or more of Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5; In particular, the induced vesicles are highly expressed by the markers Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5; In particular, the expression levels of the markers Annexin V, Flotillin-1, Cadherin 11, and Integrin alpha 5 in the induced vesicles were higher than those in MSCs or exosomes of the same origin. In particular, the inducible vesicles are highly expressed by the markers cleaved caspase-3, Calnexin, Calreticulin, CD63, CD9, caspase-3, and CD44; In particular, the tumor immunotherapy is a treatment using anti-PD-1 antibodies or anti-PD-L1 antibodies; In particular, the anti-PD-1 antibody is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, CT-011, AMP-224, MPDL3280A, MEDI4736 or MDX-1105; In particular, the anti-PD-L1 antibody is avirumab, durvalumab, or atezolizumab; In particular, the tumor is selected from solid tumors or hematologic malignancies; In particular, the solid tumor was selected from liver cancer.

5. The use of LDHA detection reagents in extracellular vesicles in the preparation of tumor diagnostic or prognostic reagents or kits; In particular, the sources of the extracellular vesicles include blood, serum, plasma, tissue, lysate, extracellular fluid, tissue fluid, lymph, cerebrospinal fluid, aqueous humor, sputum, saliva, urine, or feces; In particular, the extracellular vesicle samples were derived from cancer patients; In particular, the extracellular vesicles are derived from tumor cells; In particular, the detection reagent detects the expression level of the LDHA gene; In particular, the detection reagent detects the mRNA expression level of the LDHA gene; In particular, the detection reagent detects the protein expression level of the LDHA gene; In particular, the detection reagent is selected from at least one of the following groups: quantitative PCR dyes, quantitative PCR primers, quantitative PCR probes, antibodies, functional fragments of antibodies, or conjugated antibodies; In particular, the kit is selected from at least one of the following groups: qPCR kit, immunoblotting kit, immunochromatographic kit, flow cytometry kit, immunohistochemistry kit, ELISA kit, or electrochemiluminescence kit. In particular, the tumor is a solid tumor or a hematoma; In particular, the solid tumor is selected from liver cancer; In particular, the method for extracting extracellular vesicles includes the following steps: (1) Centrifuge the collected samples for the first time and take the supernatant; (2) Centrifuge the supernatant collected in step (1) a second time and take the supernatant; (3) Centrifuge the supernatant collected in step (2) for the third time and take the precipitate; (4) Wash the precipitate collected in step (3); In particular, the first centrifugation is approximately 500-1500g for 5-30 minutes; In particular, the second centrifugation is approximately 1000-3000g for 5-30 minutes; In particular, the third centrifugation is approximately 10,000-30,000g for 15-60 minutes; In particular, the first centrifugation is approximately 600-1500g for 5-30 minutes; In particular, the first centrifugation is approximately 600-1000g for 5-30 minutes; In particular, the second centrifugation is performed at approximately 1500-3000g for 5-30 minutes; In particular, the second centrifugation is performed at approximately 1800-3000g for 5-30 minutes; In particular, the third centrifugation is approximately 10,000-20,000g for 15-60 minutes; In particular, the third centrifugation is performed at approximately 15,000-20,000 g for 15-60 minutes; In particular, the washing process involves adding the precipitate obtained in step (3) to a washing solution, centrifuging at 10,000-30,000 g for 15-60 minutes, and collecting the precipitate to obtain the extracellular vesicles.

6. The application of an LDHA detection reagent in the preparation of prognostic diagnostic reagents or kits for cancer patients after immunotherapy; In particular, the test samples for the test reagent include blood, serum, plasma, tissue, lysate, extracellular fluid, tissue fluid, lymph, cerebrospinal fluid, aqueous humor, sputum, saliva, urine, or feces; In particular, the test sample for the detection reagent is selected from extracellular vesicles; In particular, the detection reagent detects the expression level of the LDHA gene; In particular, the detection reagent detects the mRNA expression level of the LDHA gene; In particular, the detection reagent detects the protein expression level of the LDHA gene; In particular, the detection reagent is selected from at least one of the following groups: quantitative PCR dyes, quantitative PCR primers, quantitative PCR probes, antibodies, functional fragments of antibodies, or conjugated antibodies; In particular, the kit is selected from at least one of the following groups: qPCR kit, immunoblotting kit, immunochromatographic kit, flow cytometry kit, immunohistochemistry kit, ELISA kit, or electrochemiluminescence kit. In particular, the tumor is a solid tumor or a hematoma; In particular, the solid tumor was selected from liver cancer.

7. A reagent combination or kit, wherein, The reagent combination or kit includes: Extracellular vesicle extraction kit, and LDHA detection reagents; In particular, the extraction reagent or kit for the extracellular vesicles includes extraction tools or extraction reagents; In particular, the extraction tools include blood collection tubes, centrifuge tubes, centrifuges, or pipettes; In particular, the extraction reagent includes a buffer solution; In particular, the buffer solution includes PBS; In particular, the method for extracting extracellular vesicles includes the following steps: (1) Centrifuge the collected samples for the first time and take the supernatant; (2) Centrifuge the supernatant collected in step (1) a second time and take the supernatant; (3) Centrifuge the supernatant collected in step (2) for the third time and take the precipitate; (4) Wash the precipitate collected in step (3); In particular, the first centrifugation is approximately 500-1500g for 5-30 minutes; In particular, the second centrifugation is approximately 1000-3000g for 5-30 minutes; In particular, the third centrifugation is approximately 10,000-30,000g for 15-60 minutes; In particular, the first centrifugation is approximately 600-1500g for 5-30 minutes; In particular, the first centrifugation is approximately 600-1000g for 5-30 minutes; In particular, the second centrifugation is performed at approximately 1500-3000g for 5-30 minutes; In particular, the second centrifugation is performed at approximately 1800-3000g for 5-30 minutes; In particular, the third centrifugation is approximately 10,000-20,000g for 15-60 minutes; In particular, the third centrifugation is performed at approximately 15,000-20,000 g for 15-60 minutes; In particular, the washing process involves adding the precipitate obtained in step (3) to a washing solution, centrifuging at 10,000-30,000 g for 15-60 minutes, and collecting the precipitate to obtain the extracellular vesicles. In particular, the samples include blood, serum, plasma, tissue, lysate, extracellular fluid, tissue fluid, lymph, cerebrospinal fluid, aqueous humor, sputum, saliva, urine, or feces; In particular, the reagent is a tumor diagnostic reagent or a prognostic diagnostic reagent for tumor patients after immunotherapy; In particular, the tumor is a solid tumor or a hematoma; In particular, the solid tumor was selected from liver cancer.

8. Use of the reagent combination or kit according to claim 7 in the preparation of tumor diagnostic reagents or kits or prognostic diagnostic reagents or kits for cancer patients after immunotherapy.

9. A drug combination for treating tumors, wherein, Include: Inducible vesicles, and Immunotherapy agents; In particular, the drug combination is a pharmaceutical composition or a pharmaceutical kit; In particular, the pharmaceutical composition contains a mixture of inducing vesicles and immunotherapeutic agents; In particular, the drug kit contains individually packaged inducible vesicles and individually packaged immunotherapy agents; In particular, the immunotherapy agent is a treatment using anti-PD-1 antibodies or anti-PD-L1 antibodies; In particular, the anti-PD-1 antibody is selected from ipilimumab, tremelimumab, nivolumab, pembrolizumab, CT-011, AMP-224, MPDL3280A, MEDI4736 or MDX-1105; In particular, the anti-PD-L1 antibody is avirumab, durvalumab, or atezolizumab; In particular, the tumor is a solid tumor or a hematoma; In particular, the solid tumor is selected from liver cancer; In particular, the induced vesicles are vesicles generated by inducing apoptosis in stem cells or somatic cells when they are in normal survival by adding external factors; In particular, the induction methods include adding astrocytocin, ultraviolet irradiation, starvation, or thermal stress. In particular, the stem cells are selected from mesenchymal stem cells; In particular, the mesenchymal stem cells are derived from bone marrow, dental pulp, urine, oral cavity, fat, placenta, umbilical cord, periosteum, tendon, or peripheral blood. In particular, the diameter of the induced vesicles is approximately 0.03-10 μm; In particular, the diameter of the induced vesicles is approximately 0.03-6 μm; In particular, the diameter of the induced vesicles is approximately 0.03-4.5 μm; In particular, the diameter of the induced vesicles is approximately 0.03-1 μm; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 1–1500 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 10–800 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 100–800 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 200–700 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 300–600 nM; In particular, apoptosis was induced by adding asteroidin, the concentration of which was approximately 400–600 nM; In particular, the time to induce apoptosis by adding astrosporin is approximately 2–24 hours; In particular, the time to induce apoptosis by adding astrosporin is approximately 2–15 hours; In particular, the time to induce apoptosis by adding astrosporin is approximately 2–10 hours; In particular, the induced vesicles showed higher expression of the biomarker Syntaxin 4 than MSCs or exosomes of the same origin; In particular, the markers also include one or more of Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5; In particular, the induced vesicles are highly expressed by the markers Annexin V, Flotillin-1, Cadherin 11, or Integrin alpha 5; In particular, the expression levels of the markers Annexin V, Flotillin-1, Cadherin 11, and Integrin alpha 5 in the induced vesicles were higher than those in MSCs or exosomes of the same origin. In particular, the inducible vesicles are highly expressed by the markers cleaved caspase-3, Calnexin, Calreticulin, CD63, CD9, caspase-3, and CD44.

10. A diagnostic system for tumors, wherein, The diagnostic system includes: Detection components for LDHA in extracellular vesicles derived from tumor samples, and, Result judgment component; In particular, the detection component for LDHA in the extracellular vesicles contains the reagent combination or kit of claim 7; In particular, the result determination component is used to output the risk of tumor development and / or tumor type based on the LDHA results detected by the detection component in the extracellular vesicles; In particular, the disease risk is determined by comparing the detection results of LDHA in extracellular vesicles of the test sample and the normal sample through the result judgment component. When there is a significant or extremely significant difference in LDHA in extracellular vesicles between the test sample and the normal sample, the result judgment component outputs that the test sample has a high risk of developing tumors. In particular, the tumor is a solid tumor or a hematoma; In particular, the solid tumor was selected from liver cancer.

11. A method for treating tumors, wherein, The method includes administering the pharmaceutical composition of claim 9 to a patient in need.

12. A method for diagnosing tumors, wherein, The method includes: Using the reagent combination or kit described in claim 7, the expression level of LDHA in extracellular vesicles of the sample to be tested is detected; Based on the deviation between the LDHA expression level of extracellular vesicles in the test sample and the LDHA expression level of extracellular vesicles in normal samples, it is determined whether the patient has a tumor or is at risk of developing a tumor. In particular, the LDHA expression level refers to the expression level of the LDHA gene, the mRNA expression level of the LDHA gene, or the protein expression level of the LDHA gene. In particular, when the cutoff value of LDHA expression level in extracellular vesicles in the test sample is ≥50.2000%, it is determined that the patient has a tumor or is at risk of developing a tumor. In particular, the samples to be tested include blood, serum, plasma, tissue, lysate, extracellular fluid, tissue fluid, lymph, cerebrospinal fluid, aqueous humor, sputum, saliva, urine, or feces; In particular, the method for extracting extracellular vesicles includes the following steps: (1) Centrifuge the collected samples for the first time and take the supernatant; (2) Centrifuge the supernatant collected in step (1) a second time and take the supernatant; (3) Centrifuge the supernatant collected in step (2) for the third time and take the precipitate; (4) Wash the precipitate collected in step (3); In particular, the first centrifugation is approximately 500-1500g for 5-30 minutes; In particular, the second centrifugation is approximately 1000-3000g for 5-30 minutes; In particular, the third centrifugation is approximately 10,000-30,000g for 15-60 minutes; In particular, the first centrifugation is approximately 600-1500g for 5-30 minutes; In particular, the first centrifugation is approximately 600-1000g for 5-30 minutes; In particular, the second centrifugation is performed at approximately 1500-3000g for 5-30 minutes; In particular, the second centrifugation is performed at approximately 1800-3000g for 5-30 minutes; In particular, the third centrifugation is approximately 10,000-20,000g for 15-60 minutes; In particular, the third centrifugation is performed at approximately 15,000-20,000 g for 15-60 minutes; In particular, the washing process involves adding the precipitate obtained in step (3) to a washing solution, centrifuging at 10,000-30,000 g for 15-60 minutes, and collecting the precipitate to obtain the extracellular vesicles. In particular, the tumor is a solid tumor or a hematoma; In particular, the solid tumor was selected from liver cancer.